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Cancer is a leading cause of death worldwide. Oesophageal cancer in particular is the sixth most 
common cause of cancer deaths globally and its incidence and mortality rates in Southern Africa 
are among the highest in the world. One of the major challenges with cancer treatment is the vast 
variability in patient response to chemotherapy, which is predominantly due to genetic variability. 
The most relevant genes in this context encode the CYP and GST drug metabolising enzymes 
(DMEs) as these enzymes metabolise up to 90% of clinically-prescribed medication.  Patients are 
also exposed to a variety of other compounds that along with chemotherapeutic drugs may alter 
DME gene expression. Changes in DME gene expression influence the therapeutic outcomes for 
patients; thus, understanding the effects of drugs and compounds on the expression of DMEs is 
crucial for the advancement of personalised medicine.  
The aim of this study was to determine the effects of two commonly-used chemotherapeutic drugs, 
as well as a CYP-inducing compound, on the differential expression of four pharmacogenetically 
relevant DME-encoding genes, CYP1A1, 1A2, 1B1 and GSTP1, in a human oesophageal cancer 
cell line.  
WHCO1 cells (derived from a human oesophageal squamous cell carcinoma) were treated with the 
chemotherapeutic drugs 5-fluorouracil (5-FU), cisplatin (CDDP), and the model CYP-inducer 
benzo[a]pyrene (BP). Total RNA and proteins were extracted from the cells at various time points 
following treatment. Changes in CYP1A1, CYP1A2, CYP1B1 and GSTP1 gene expression were 
determined by quantitative real-time PCR, and the corresponding changes in protein expression 
were determined by western blotting. 
In most cases, CYP mRNA expressions were slightly but significantly enhanced by 5-FU but 
down-regulated by CDDP exposures alone, and as predicted, BP led to a robust increase in 
expression of all three CYP genes. The changes in mRNA levels observed with 5-FU or CDDP 
alone were mostly not reflected at the protein level. Additionally, the induction levels of CYP1A1 
and CYP1A2 mRNA caused by BP were lower in the presence of 5-FU or CDDP, particularly 24 
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hours following drug treatment, which were reflected at the protein levels. On the other hand, 
CYP1B1 mRNA and protein expressions caused by BP were lower at earlier time points in the 
presence of 5-FU, but enhanced in the presence of CDDP.  GSTP1 mRNA expression was 
significantly affected by both 5-FU and CDDP, whilst GSTP1 protein expression remained 
unaffected by the treatment with any of the compounds. Additionally, combining either 5-FU or 
CDDP with BP induced early apoptosis in the WHCO1 cells.  
The commonly-used chemotherapeutic drugs 5-FU and CDDP influenced the mRNA expression 
levels, and in some cases, the corresponding protein expression levels, of four pharmacogenetically 
important DMEs, both individually and in the presence of BP. This has important clinical 
consequences for oesophageal cancer patients undergoing chemotherapy, who are prescribed drugs 
including 5-FU and CDDP, and are also likely to be exposed to CYP-inducing medications and 
compounds on a daily basis. Furthermore, the observed induction of tumour cell apoptosis by the 
combination treatments may suggest a potential mechanism for improving current chemotherapy. 
These findings provide the basis for future pharmacogenetics research, which is key to the 
progression towards personalised medicine, a field that holds promise as a means to ensure greater 
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1. 1 Cancer epidemiology and treatment 
 
Cancer is a leading cause of death worldwide, and has been identified by the World Health 
Organisation as one of the four primary threats to human health and development. There were 14.1 
million new cancer diagnoses across the world in 2012, responsible for 8.2 million deaths. It has 
been estimated that by the year 2030, there will be 22.2 million new cancer cases and over 13.1 
million cancer deaths annually. Currently, cancers of the breast, prostate, lungs, colorectum and 
cervix constitute the most common cancers globally and account for more than half of all cancer 
deaths (GLOBOCAN 2012, IARC). 
About 65% of all cancer deaths occur in low to middle-income countries. In Africa, the burden of 
cancer has been estimated to increase from 715,000 new cases and 542,000 deaths in 2008, to 
double by the year 2028 (Bray et al., 2012). The incidence and mortality patterns of cancers in 
Africa vary greatly across regions. In Southern Africa, oesophageal cancer is among the top five 
most common cancers (Figure 1.1).  
1.1.1 Oesophageal cancer in Southern Africa 
 
Oesophageal cancer is the fourth most common cancer among males and the fifth most common 
among females, in Southern Africa (Figure 1.1). Furthermore, it is the sixth most common cause of 
cancer deaths globally, with an estimated 400,000 deaths in 2012. Generally, oesophageal cancer 

















Southern Africa exhibits some of the highest mortality rates for oesophageal cancer worldwide 
(Figure 1.2), with a rate of 12.8 (per 100,000) in men, second only to Eastern Asia (14.1), and a 
rate of 6.2 in women, second to Eastern Africa (7.3). Compared to other parts of Africa, the 
incidence and mortality rates of oesophageal cancer in Southern Africa are over 7 times higher 
among men and 4 times among women. In particular, the East Cape Province (former Transkei 
area) of South Africa has recorded exceptionally high incidence and mortality rates for 
oesophageal cancer, accounting for as much as 80% of all cancer deaths (Somdyala et al., 2010). 
As is the case in many Western countries, tobacco-smoking and alcohol consumption have been 
linked to the high incidence of oesophageal cancer in the Eastern Cape; however, these factors are 
not sufficient to explain the high incidence on a global scale (Cook, 1971). Dietary deficiencies are 
also thought to be responsible for the development of oesophageal cancer in this region, and 
additionally, fungal toxins from home-grown maize (Gelderblom et al., 1988; Marasas et al., 1988; 
Figure 1.1 Ranking of cancers by incidence and mortality in Southern Africa. 
Oesophageal cancer ranks as the fourth most common cancer in males (left) and the fifth most 
common cancer in females (right). Age-standardised rate (ASR or W) refers to the number of new 
cases or deaths per 100,000 people per year, in a population with a standard age structure. (Adapted 




Pacella-Norman et al.,2002). The survival rate of oesophageal cancer when compared to other 
cancers is particularly poor, with a 5-year survival rate of just 5-10%, with 75% of patients dying 
within one year of diagnosis (Hiyama et al., 2007). There is therefore an urgent need for new and 
more effective treatment regimens to improve the outcome for these patients.  
 
 
The modality of treatment is specific to the type and stage of the cancer (e.g. type and stage of 
cancer, solid tumours vs. haematological malignancies) as well as a variety of patient factors (e.g. 
age, concomitant disease) and socioeconomic factors (e.g. access to healthcare). In most cancer 
cases, early detection significantly improves prognosis and outcomes for the patient. Once the 
patient has been through a complete evaluation, which includes the patient’s history, physical 
examination, and various other procedures, the type of cancer and stage is diagnosed. Based on the 
diagnosis, there are numerous possible options for treatment (Pollock and Morton, 2000). For most 
solid tumours, surgery represents the oldest form of cancer treatment, and, though not without its 
Figure 1.2 Map depicting the global burden of oesophageal cancer. Southern Africa displays some 
of the highest mortality rates for oesophageal cancer worldwide. Rates are age-standardised and are given per 
100,000 people. (Adapted from http://www.globocan.iarc.fr, GLOBOCAN 2012, IARC) 
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own risks, has a high success rate in the eradication of localised primary tumours. Radiation 
therapy is also highly effective at targeting both localised tumours and non-solid cancers such as 
leukaemia, although, depending on the specific cancer being treated, surrounding tissues and 
organs may be damaged by the ionising radiation resulting in harmful side-effects for the patient 
(Urruticoechea et al., 2010) . Radiation therapy is often administered in combination with surgery, 
and/or chemotherapy. Targeted therapies (e.g. imatinib, a tyrosine-kinase inhibitor, used for the 
treatment of leukaemia), immunotherapy (e.g. rituximab, a chimeric monoclonal antibody against 
CD20 of B cells, used for the treatment of leukaemia and lymphoma) and angiogenesis inhibitors 
(e.g. bevacizumab, a chimeric monoclonal antibody against vascular endothelial growth factor A, 
used for the treatment of various solid tumours) are all examples of modes of cancer treatment that 
show varying levels of success and each exhibit their own set of side effects or complications for 
the patient. The sections which follow will focus on chemotherapy, and more specifically, on 5-




Cancer chemotherapy first emerged in the 1960s, prior to which surgery and radiation therapy 
formed the only means of cancer treatment. Since the advent of chemotherapy, over 50 different 
drugs have become available. Chemotherapeutic drugs are cytotoxic agents that target rapidly 
dividing cells, a characteristic of cancer cells, through various mechanisms. These drugs are 
administered by a number of different methods, including oral, topical and intravenous (IV) 
administration, and are usually given over different time cycles and in combinations to form 
specific treatment regimens and schedules. Generally, chemotherapy can be given alone or in a 
neo-adjuvant (pre-surgery), adjuvant (post-surgery) or palliative manner. The nature of 
chemotherapeutic drugs is such that it presents with extremely high toxicity to non-cancerous 
tissues, has a 30% success rate and varies greatly in patient response. Currently, the majority of 
chemotherapeutic drugs available are associated with serious adverse drug reactions (ADRs) (Dos 
Santos et al., 2012). Additionally, deciding on the correct drug dose to achieve maximal 
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therapeutic proficiency while minimising adverse side effects is a great challenge to oncologists, 
due to the fact that each patient is unique and responds differently to the chemotherapeutic drugs. 
As a result, palliative care becomes vitally important in ensuring that the patient is able to cope 
with ADRs which include nausea, vomiting, diarrhoea, fatigue and pain. More severe side effects, 
including cardiac dysfunction and nephrotoxicity, can be fatal, and may only manifest years after 
chemotherapy.  Table 1.1 shows some commonly used chemotherapeutic drugs, their commercial 
names, targeted cancers and some of their known side effects.  
Table 1.1 Examples of commonly-used chemotherapeutic drugs. The commercial names, targeted 
cancers and some known side effects of the drugs are also listed. (Adapted from 
http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs) 
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5-Fluorouracil (5-FU) is one of the most commonly-used chemotherapeutic drugs for the treatment 
of a wide variety of malignancies, including breast, gastrointestinal, oesophageal, cervical, skin 
and lung cancer (Poorter et al., 1995; Oguri et al., 2005; Ofverholm et al., 2010). The drug was 
synthesised over 50 years ago, upon the discovery that fluorine markedly inhibited tumours in mice 
(Heidelberger et al., 1957).  
5-FU is administered orally, topically, by IV injection or by slow IV infusion, either alone or in 
combination with other drugs (Matsuyama et al., 2008). For example, 5-FU forms part of the ECF 
(Epirubicin + Cisplatin + 5-FU) regimen for pre- and post-operative chemotherapeutic treatment of 
oesophageal cancer patients, and part of the MCF (Methotrexate + Cyclophosphamide + 5-FU) 
regimen, one of the oldest regimens for breast cancer (Cunningham et al., 2006 and 2008). Dosage 
is based on the type of cancer and the method of administration, and can vary from 25 mg/m
2
 
(body surface area) orally, to 2000 mg/m
2
/day over a 96-hour slow IV infusion (McAuley, 2012). 
The pharmacokinetics of 5-FU is characterised by a high drug clearance rate and a short 
distribution period, with an elimination half-life of 8 to 14 minutes (Schilsky, 1998).  
One of the predominant toxic effects of 5-FU in patients is myelo-suppression, which manifests as 
neutropenia, anaemia or thrombocytopenia, consequently raising the risks of infection and 
bleeding. Other adverse reactions include cardiotoxicity, dermatitis, mucositis of the 
gastrointestinal tract, and long-term negative impact on cognition (Kimura and Okuda, 1999; Alter 
et al., 2006; Wigmore et al., 2010).  
1.1.4 Mechanisms of action and metabolism of 5-FU 
 
For 5-FU to exert its effects, it must be anabolised to its active forms by the sequential actions of a 
series of enzymes, including orotate phosphoribosyltransferase (OPRT) with phosphoribosyl 
pyrophosphate (PRPP) as the cofactor, uridine kinase (UK), uridine phosphorylase (UP), 
ribonucleotide reductase (RR) and thymidine kinase (TK). The three main active metabolites are 
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fluorouridine triphosphate (FUTP), fluorodeoxyuridine triphosphate (FdUTP) and 
fluorodeoxyuridine monophosphate (FdUMP), and each one utilises different cytotoxic 
mechanisms (Longley et al., 2003). 
The action of FUTP demonstrates the rationale behind the development of 5-FU: the “decoy 
molecule”.  As the name of the drug denotes, the chemical structure of 5-FU is analogous to that of 







Consequently, during RNA synthesis, FUTP is incorporated instead of UTP, resulting in profound 
inhibitory effects on the synthesis, processing and stability of RNA. The other active metabolite 
FdUTP can be incorporated into DNA to a certain extent, which causes a halt in DNA elongation 
during DNA replication and leads to fragmentation of the strand (Diasio and Schuetz, 1985). 
Although the decoy concept originally formed the basis for the synthesis of 5-FU as a 
chemotherapeutic agent, 5-FU is now known primarily as a thymidylate synthase (TS) inhibitor. 
TS is responsible for the synthesis of thymidine triphosphate (TTP), one of the four nucleotide 
triphosphates involved in in vivo DNA synthesis. The third 5-FU active metabolite, FdUMP, is 
able to inhibit TS activity resulting in TTP depletion and hence stunted DNA synthesis and 
impaired cell growth. This property of 5-FU has been described as its most significant anti-tumour 
effect (Van Kuilenburg et al., 2004).  
Figure 1.3 Structural differences between uracil and 5-FU.  (Adapted from Peer et al., 2012) 
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Whilst the anabolic pathway of 5-FU leads to anticancer effects, the catabolic pathway is 
responsible for approximately 85% of 5-FU metabolism (Ezzeldin and Diasio, 2004). The 
dihydropyrimidine dehydrogenase (DPD) enzyme is key to regulating the bioavailability of 5-FU 
and converts it to the inactive form dihydrofluorouracil (DHFU). In both normal and tumour cells, 
the activity of 5-FU is thus dependant on the amount of DHFU present in the cell (Longley et al., 












Figure 1.4 Metabolic pathway of 5-FU. 5-FU is primarily eliminated by conversion to inactive DHFU 
by DPD in the liver. The remainder of the 5-FU is converted by a series of enzymes into three main active 
metabolites, FUTP, FdUTP and FdUMP. These metabolites result in RNA damage, DNA damage and DNA 







Cisplatin, also known as cis-diamminedichloroplatinum(II) (CDDP) is an alkylating agent that was 
the first member of a class of platinum-containing chemotherapeutics, which now also includes 
carboplatin and oxaliplatin. CDDP compound was first described in 1845, and then accidentally 
found to be effective against cell proliferation during a study on E.coli growth 20 years later 
(Rosenberg et al., 1965). Today, CDDP is highly effective in the treatment of a variety of cancers, 
including testicular, ovarian, oesophageal, bladder, lung, gastric and cervical tumours.  
CDDP is administered by short IV infusion or by direct abdominal infusion in the case of gastric 
tumours. It can be used alone or in combination with other drugs, for example, the CMV (CDDP + 
Methotrexate + Vinblastine) neo-adjuvant regimen for bladder cancer, the DCF (Docetaxel + 
CDDP + 5-FU) regimen, or the CDDP + 5-FU regimen combined with radiotherapy, both for the 
treatment of oesophageal cancer (Van Cutsem et al., 2006). The compound has a half-life of 20-30 
minutes, and as is the case with most chemotherapeutic drugs, CDDP dosage ranges greatly (20-
150 mg/m
2
) depending on patient and tumour-related factors (Candelaria et al., 2006; Helm and 
States, 2009). 
Although CDDP is considered an extremely potent anti-neoplastic agent, its clinical application is 
limited by severe nephrotoxicity (Townsend et al., 2003; Pabla and Dong, 2008). Other adverse 
effects include hearing loss, hepatotoxicity, neurotoxicity and myelo-suppression (Wang and 
Lippard, 2005). 
1.1.6 Mechanisms of action and metabolism of CDDP 
 
CDDP is a small molecule that consists of a platinum (Pt) ion, two chloride ions and two ammonia 
molecules (Figure 1.5). The mechanism of action of CDDP entails the cross-linking of DNA 
through aquation, i.e. when the molecule enters the cell, one of the chloride ions is displaced by 
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water. This allows the Pt atom to bind to guanine bases in the DNA strand, eliciting DNA repair 
mechanisms, which in turn triggers apoptosis and cell cycle arrest due to the inability of the cell to 





The metabolic fate of CDDP has not been as well characterised as that of other chemotherapeutic 
drugs such as 5-FU (Dos Santos et al., 2012). Thus, the general pathways for the metabolism of all 
Pt-containing drugs will be discussed.  
The influx of Pt-containing compounds into the cell is controlled by the membrane-bound protein 
SLC31A1, and the efflux by ABCC2, ABCG2, ATP7A and ATP7B (Figure 1.6). Once the Pt-
containing compound is inside the cell nucleus, its main anti-tumour mechanism is the formation 
of Pt-DNA adducts, which results in cell cycle arrest and apoptosis. These Pt-DNA adducts are 
recognised by the high-mobility group box-1 (HMGB1) protein, which activates cellular responses 
to the adducts. These responses includes the signalling of mismatch repair enzymes such as MLH1 
and MSH6, as well as nucleotide excision repair enzymes such as XRCC1, ERCC1, ERCC2 and 
XPA. These enzymes detect breaks in the DNA and remove proteins from the DNA helix, 
rendering the helix more accessible to repair enzymes such as POLH and POLB. Many of the 
above-mentioned repair enzyme genes have known variants that lead to successful repair of the 
cross-linked DNA, thus causing decreased drug efficiency (Sakano et al., 2006; Van der Straaten et 
al., 2006). Additionally, there are numerous enzymes that are responsible for the detoxification of 
Pt-containing drugs in the cell, and thus play a key role in cellular drug resistance (Figure 1.6). 
Figure 1.5 Structure of a CDDP molecule. (Adapted from Lovejoy et al., 2008). 
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Among these is the glutathione-S-transferase-π (GSTP1) enzyme, which forms part of a group of 
enzymes referred to as drug metabolising enzymes (DMEs) and which will be discussed in more 
















1.2 Drug metabolising enzymes: role in drug response and effects of chemotherapeutics 
 
There are several factors that affect cancer patient response to treatment, and chief among them is 
the variability in the metabolism of chemotherapeutic drugs. Most of the currently used 
chemotherapeutics are substrates for DMEs, particularly the cytochrome P450 (CYP) enzymes, 
which form the basis of this study. These DMEs activate, deactivate and detoxify foreign 
Figure 1.6 Metabolic pathway of Pt-containing drugs. Once Pt enters the cell, it exerts its anti-
proliferative effect by forming DNA adducts. A number of different mismatch repair and nucleotide excision 
repair enzymes attempt to repair the damaged DNA, once the damage has been recognised by the HMGB1 
protein. Pt is detoxified by enzymes such as GSTP1. (Obtained from Sharon et al., 2009) 
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compounds in the human body, through catalysing various biochemical modifications of 
xenobiotics (e.g. drugs), as well as endogenous chemicals (e.g. hormones). Through their activities, 
DMEs are therefore able to convert drugs into pharmacologically active metabolites and hence 
influence the susceptibility of tissues and organs to the therapeutic and toxic effects of these drugs 
(Li and Bluth, 2011).  
The DMEs exhibit broad substrate selectivity, but the genes encoding them exhibit genetic 
polymorphisms which affect their expression and activity, which in turn leads to variability in the 
response to chemotherapeutic drugs. This genetic variability accounts for up to 90% of the wide 
range in therapeutic response observed from patient to patient (Wrighton and Stevens, 1992; 
Scripture et al., 2005; Code et al., 1997).  Genetic variations in DME genes have been shown to 
lead to decreased intracellular enzyme concentrations, dysfunctional or structurally altered 
enzymes with functional consequences. Subsequently, the metabolism of drugs is compromised or 
altered, and the efficacy of treatment may be affected (Ekhart et al., 2009). As an example, 40-50% 
of patients experiencing severe toxicity to 5-FU have been shown to possess a deficiency in the 
DME DPD, as a result of a single nucleotide polymorphism (SNP) in the DPD gene (Ezzeldin and 
Diasio, 2004). Additionally, severe toxicities induced by the anticancer drug irinotecan have been 
shown to be linked to a genetic polymorphism in the uridine diphosphate glucuronosyltransferase 
DME gene (Fakih et al., 2007). Therefore, genetic variations in DMEs which alter metabolic 
capacity can be responsible for some patients being poor metabolisers (PMs) and experiencing 
toxic build-up of the drug, or for other patients to be ultra-rapid metabolisers (UMs) and 
experiencing decreased efficacy of treatment.  
Considering the importance of DMEs in predicting therapeutic outcomes, it is crucial to understand 
how drugs may affect DME gene expression levels. Increased expression of a particular DME gene 
will result in increased drug clearance and decreased efficiency; conversely, decreased expression 
of the DME will lead to decreased drug clearance and increased efficiency, but could also lead to 
toxicity due to elevated drug concentrations. The outcome is dependent on the specific function of 
the DME, and this outcome will vary between patients due to differential expression. For example, 
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an improved response to the chemotherapeutic drug docetaxel, used in the treatment of breast 
cancer, was correlated with low mRNA and protein expression level of the DME CYP3A4, which 
functions to deactivate this drug (Iwao-Koizumi et al., 2005).  In some cases the opposite effect is 
expected, such as when medications are administered as pro-drugs.  A pro-drug is a compound that 
is administered to the body in an inactive or less than fully active form, requiring activation by 
metabolic enzymes to become functional, for example codeine, which requires DME activation to 
form the functional morphine (Zanger and Schwab, 2013). Figure 1.7 shows the consequences of 
under- and over-expression of a CYP gene for a hypothetical patient administered a drug and a pro-
drug metabolised by the CYP. These examples serve to illustrate the importance of DME gene 









While the variability of drug response can be explained, at least partially, by the genetic variations 
in the genes coding for DMEs, the effects of the chemotherapeutic drugs themselves on the 
expression of DMEs have been poorly studied. Such effects are vital in understanding patient 
• Drug metabolism too slow 
• Drug levels too high at typical 
dosage 
• High risk for drug toxicity 
• No response to pro-drug 
Under-expression of 
CYP (PMs) 
• Drug metabolism too rapid 
• Drug levels too low at typical 
dosage 





Figure 1.7 Consequences of under- and over-expression of CYP genes. When CYP is under-
expressed, patients can be poor metabolisers (PMs) and when CYP is over-expressed, patients can be 
ultra-rapid metabolisers (UMs). In both cases, this results in treatment failure, illustrating the importance 
of DME expression in drug response. 
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response. As an example, the drug itself may affect its own metabolism by increasing or decreasing 
DME gene expression, depending on the dosage used. Alternatively, a chemotherapeutic agent 
may influence the gene expression of DMEs required to detoxify other drugs or chemicals within 
the patient’s body. In the case of 5-FU in particular, there are few studies on the effects of the drug 
on DME gene expression, especially the CYP1 DMEs, which will be discussed in more detail in 
section 1.4.1. Using mouse models, Afsar et al. (1996) has shown that 5-FU treatment down-
regulates hepatic CYP2C11 and CYP3A isoenzymes at the protein level, and Yoshisue et al. 
(2001) has demonstrated that exposure to 5-FU causes a decrease in small intestinal CYP1A1/2 
and CYP3A isoenzyme levels. Another study has shown that 5-FU has little or no inhibitory effect 
on CYP-catalysed reactions in human liver microsomal preparations (Park and Kim, 2003). 
Generally, most studies using human cells focus on the effects of 5-FU on the expression of DPD, 
TS and OPRT (Yoshisue et al., 2001; Takechi et al., 2002; Oguri et al., 2005; Oeda et al., 2006; Li 
et al., 2007; Li et al., 2013), as these are the genes involved in 5-FU metabolism. However, as the 
CYP DMEs contribute to the metabolism of over 90% of clinically-prescribed drugs, the potential 
effects of 5-FU on the CYPs need to be elucidated, and this has yet to be fully described (Motawi et 
al., 2013).  
In the case of CDDP, a previous study using rat kidney cortex cells has shown that CDDP is 
capable of reducing intracellular glutathione, as well as several CYP enzyme levels (Bompart, 
1989). However, the majority of studies have since focussed on CYP2E1, as elevated levels of this 
enzyme have been shown to enhance CDDP-induced hepatotoxicity through the production of 
reactive oxygen species (ROS) (Liu et al., 2002; Liu and Baliga, 2003; Lu and Cederbaum, 2007; 
Martins et al., 2008). Masek et al. (2009) performed a study showing a minor inhibition of 
CYP2C9 and CYP2B6 enzyme levels in response to CDDP treatment. In addition, the GSTP1 
DME is of interest as increased expression levels of this protein may have a protective effect 
against CDDP-induced cytotoxicity, but may also lead to cellular resistance to the drug (Yellin et 
al., 1994; La Pensee et al., 2009; Sharon et al., 2009; Townsend et al., 2009; Sahu et al., 2013).  
This is because GSTP1 is one of the main enzymes responsible for the detoxification of CDDP, 
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resulting in lowered concentrations of the drug in the cells (Peklak-Scott et al., 2008). As is the 
case with 5-FU, more human cell studies on the effects of CDDP on DME expression, especially 
the CYP1 enzymes, are required in order to better understand patient response to this widely-
utilised chemotherapeutic drug.  
1.3 Administered drugs and other compounds as substrates, inducers or inhibitors of DMEs 
 
In addition to drugs, it is important to understand the potential effects on DME genes caused by 
substances that a cancer patient would likely be exposed to on a daily basis through the patient’s 
immediate environment or lifestyle habits. Whilst oesophageal cancer has many genetic risk 
factors, including somatic mutations and polymorphisms in the DME genes, there is also a host of 
environmental risk factors that have been linked to oesophageal tumour development. One of the 
most well-characterised of these factors is tobacco-smoking, due to exposure to benzo[a]pyrene 
(BP) (Wogan et al., 2004; Ye and Xu, 2010). It has been shown that many head and neck cancer 
patients continue to smoke or are exposed to secondary tobacco smoke during treatment; in some 
cases, 30% of patients continue cigarette smoking after diagnosis (Duffy et al., 2007; Chen et al., 
2011; Kashigar et al., 2013). For an oesophageal cancer patient that is exposed to BP in cigarette 
smoke, it is important to understand the effects of chemotherapeutic drugs on DME expression in 
the presence of BP, as the ratio of activity between the CYP enzymes, particularly CYP1A1 and 
CYP1B1 which metabolise BP, and the detoxification enzymes such as GSTP1, is crucial for the 
prevention of toxic build-up of reactive BP intermediates (Liang et al., 2003).  Whilst BP is a 
substrate of CYP activity, it also acts as an inducer of CYP activity by activating the 
arylhydrocarbon receptor (AhR) signalling pathway (Figure 1.8), to induce transcription of genes 
such as CYP1A1, CYP1A2 and CYP1B1. The AhR pathway will be briefly explained.  The first 
step in the pathway is the interaction of a foreign compound with the ligand-activated AhR in the 
cytosol of the cell (Figure 1.8, step 1). 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and the 
commonly-used drug omeprazole depicted in Figure 1.8, are also examples of potent inducers of 
CYP1 expression (Yoshinari et al., 2008). This ligand binding triggers a conformational change in 
the AhR, which in turn exposes a nuclear localisation signal (NLS) allowing translocation of the 
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bound AhR from the cytosol to the nucleus (step 2). Heat shock protein 90 (HSP90) and ligand 
both remain bound to the AhR during this translocation. Once in the nucleus, the AhR dimerizes 
with AhR nuclear translocator (ARNT) to form an active transcription factor that recognises the 
dioxin response element (DRE) motif in the promoter region of the target genes (step 3). The final 
steps in the pathway entail an increase in mRNA of these genes (step 4), and ultimately, increased 
production and exportation of the corresponding proteins (step 5). Increases in CYP1 mRNA and 
subsequent increases in CYP1 protein are often used as markers of AhR activation (Israel and 












Therefore, it is important to include BP in this study not only due to its presence in substances that 
a patient may be exposed to, like tobacco, but also as a model inducer of CYP expression. This is 
because inducers of CYPs are in abundance in the environment. BP is classified as a polycyclic 




Figure 1.8 Schematic representation of the AhR/ARNT signalling pathway. The AhR is a 
ligand-activated transcription factor. Ligand binding to the AhR (step 1) triggers transport of the AhR to the 
cell nucleus, with the aid of HSP90 and NLS (step 2), followed by dimerization of the AhR with ARNT 
(step 3) to recognise DREs and up-regulate transcription of toxic response genes such as CYP1A1 (step 4). 
This results in increased production of the relevant proteins and their exportation from the cell (step 5). 




pollutants, found not only in cigarette smoke but also in processed fossil fuels (e.g. motor exhaust 
fumes), meat and fish cooked at high temperatures (e.g. grilling or barbecuing) and a variety of 
culinary oils (e.g. coconut oil) (Alomirah et al., 2010; Perumal et al., 2012). Therefore, there are 
numerous environmental PAHs other than BP that a cancer patient may be exposed to and that may 
affect DME expression. In addition to the PAHs, dietary substances also present with potential 
effects on CYP expression. A well-studied example is grapefruit juice, from which bio-active 
compounds have been shown to result in rapid, irreversible and sustained inhibition of CYP3A4 
and in some studies, varying levels of inhibition of CYP1B1 (Ohta et al., 2002; Girennavar et al., 
2006). In fact, it is well-established that ADRs occur in patients regularly consuming grapefruit 
juice whilst taking benzodiazepines, which are largely metabolised by CYP3A4 and are 
administered to treat anxiety, insomnia or even as pre-medication for certain medical procedures 
(Ozdemir et al., 1998; Evans, 2000). Other strong exogenous inducers or inhibitors of DMEs have 
been found in numerous commonly-used herbal products that are sold over-the-counter, such as St. 
John’s Wort, which is a well-known a CYP3A4 inducer that is used for the treatment of depression, 
and Gingko biloba, which acts as a CYP1A2 inducer and is used for the general enhancement of 
cognitive functions such as memory and concentration (Hellum et al., 2007). Thus, it is plausible 
that a cancer patient may be consuming foods or nutritional/herbal supplements that contain 
compounds capable of influencing DME expression.  
Although many studies focus on the effect of one drug at a time, in reality, cancer patients are 
administered several chemotherapeutic drugs simultaneously, as well as other medication to treat 
side effects and possibly unrelated acute or chronic conditions. The drugs themselves can act not 
only as substrates for DMEs, but also as inducers or inhibitors of DME gene expression. For an 
individual who is administered multiple chemotherapeutic drugs and/or other concurrent 
medication prescribed for the treatment of other conditions, this may have significant clinical 
consequences. For example, adverse reactions have arisen from interactions between the 
chemotherapeutic drug capecitabine (the orally-active pro-dug of 5-FU) and the anticoagulant 
warfarin, when 5-FU down-regulates CYP2C9 expression, which is essential for warfarin 
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metabolism (Giunta, 2010). Another example is lidocaine, a commonly-used local anaesthetic and 
antiarrhythmic agent, which is predominantly metabolised by the CYP1A2 enzyme. The anti-
depressant fluvoxamine is a potent inhibitor of CYP1A2, hence when these drugs are administered 
together, the inhibition of CYP1A2 by fluvoxamine considerably reduces lidocaine metabolism, 
thus increasing the risk of lidocaine toxicity (Isohanni et al., 2006). These two classic examples of 










Therefore, the use of BP in this study is not only due to its presence in the environment, but also 
due to its utility as a model CYP-inducing compound, from which inferences can be made about 
other CYP-inducing compounds that a cancer patient on chemotherapy may be exposed to, such as 
environmental substances (e.g. PAHs), dietary compounds (e.g. nutritional supplements like 
Gingko biloba) and drugs (e.g. the anticoagulant warfarin). Many conventional studies do not 
include the interrogation of the possible influence of these other exogenous compounds on the 
metabolism of clinical drugs. Nevertheless, it is important that the possible combinatorial effect of 











Figure 1.9 Examples of the effects of co-administered drugs on CYP expression. Warfarin is 
an anticoagulant drug metabolised by CYP2C9, and when the chemotherapeutic drug 5-fluorouracil is 
taken at the same time, CYP2C9 is inhibited, resulting in toxic accumulation of warfarin (left). Similarly, 
lidocaine is an anaesthetic and antiarrhythmic drug metabolised by CYP1A2, and the co-administration 




undertaking studies of this nature, in order to better understand clinical implications for patients. 
This approach will provide better insight into the potential for improving existing cancer therapies. 
 
1.4 DMEs to be focussed on in this study 
 
1.4.1 Cytochrome P450s 
 
The human CYP super-family represents the most important system responsible for catalysing the 
oxidation of most drugs (Nelson, 2004; Guengerich, 2006). The CYPs are also key enzymes to 
consider in cancer treatment as well as cancer formation, because they catalyse the activation and 
deactivation of anticancer drugs as well as the metabolic activation of pro-carcinogens such as the 
previously-mentioned BP (Rodriguez-Antona andIngelman-Sundberg, 2006). In addition to the 
liver, CYP proteins are also found in almost every extra-hepatic organ in humans, and expression 
levels of CYP genes have been found to vary up to 60-fold from one individual to the next as well 
as between tissue types (Nebert and Dalton, 2006; Sulem et al., 2011). 
In this study, the focus will be on three CYP genes belonging to the CYP1 family, namely 
CYP1A1, CYP1A2 and CYP1B. The highly-conserved CYP1A1 (MIM #108330) and CYP1A2 
(MIM #124060) genes map to chromosome 15q24.1, and span 6 kb and 7.8 kb respectively, with 
CYP1A1 encoding a 512-amino acid protein, whilst CYP1A2 is 516 amino acids long (Spurr et al., 
1987).  CYP1B1 (MIM #601771) is a 12 kb gene located at chromosome 2p22.2, encoding a 543 
amino acid protein, making it the largest human CYP (Murray et al., 2001). CYP1A2 is one of the 
most highly-expressed constitutive CYP genes detectable in the liver, whilst CYP1A1 and CYP1B1 
are mainly expressed in extra-hepatic tissues.  
As previously explained, the expression of the CYP1 genes is inducible via the AhR pathway 
(Figure 1.8), and there are many substances, including clinically-used drugs, that are known CYP1 
inducers. For example, the broad-spectrum anthelmintic drug albendazole, which is used for 
treating a variety of parasitic worm infestations, is a known inducer of CYP1A1/1A2 (Asteinza et 
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al., 2000; Bapiro et al., 2002).  Additionally, carbamazepine is administered for the treatment of 
epileptic seizures and is known to be an inducer of CYP1A2 expression, whilst the 
chemotherapeutic drug doxorubicin is a CYP1B1 inhibitor (Rochat et al., 2001; Parker et al., 
1998). In some cases, such as in the case of BP, the inducer may also be a CYP1 enzyme substrate. 
As explained in detail in section 1.2, some studies have investigated the effects of the 
chemotherapeutic drugs 5-FU and CDDP on the expression of the CYPs, but many questions 
remain to be answered, particularly, what the effects of these drugs on the important DMEs are in 
human cancer cells, and furthermore, how these effects may vary in the presence of compounds 
which alter CYP expression. It is important to understand these effects because they may have an 
impact on the metabolism of co-medication such as the examples given above. Furthermore, ADRs 
may arise from the interactions of co-administered drugs that affect CYP expression, as mentioned 
in section 1.3 (Figure 1.9). This highlights the significance of investigating the effects of 5-FU and 
CDDP on the expression of the CYP genes. 
1.4.2 Glutathione-S-transferases  
 
Another DME which will be investigated in this study is a member of the glutathione-S-transferase 
(GST) super-family, GSTP1. This family of detoxification enzymes, classically viewed as part of 
the cell’s defence against harmful chemicals produced endogenously and in the environment, 
catalyse the conjugation of glutathione to a range of hydrophobic and electrophilic compounds, 
resulting in water-soluble metabolites for excretion from the body. The GSTP1 gene (MIM 
#134660) is located on chromosome 11q13.2, spans 3 kb and encodes a 210 amino acid protein. 
GSTP1 represents the major GST expressed in extra-hepatic tissues such as the oesophagus and 
lungs, with minimal expression in the liver (Rowe et al., 1997; Sherratt et al., 1997; De Bruin et 
al., 2000). As is the case with CYP1B1 expression, GSTP1 exhibits over-expression in malignant 
tissues in comparison with their matched normal tissues (McIlwain et al., 2006).  
The gene expression level of GSTP1 is an important determinant of patient response to drugs. 
Over-expression of GSTP1 is thought to confer resistance to chemotherapy, as has been 
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demonstrated in breast cancer (Su et al., 2003; Arai et al., 2008), and elevated expression levels is 
also associated with poor prognosis in a variety of other cancers including colorectal cancer 
(Mulder et al., 1995; Sutoh et al., 2000).  This is because over-expression of GSTP1 results in 
accelerated detoxification of the drug, and therefore a decrease in drug effectiveness, or acquired 
resistance. However, the detoxifying action of GSTP1 is critical for protection against pro-
carcinogenic compounds such as BP. It is therefore of obvious importance to know the effects of 
chemotherapeutic drugs, as well as concomitant medication or other harmful exogenous 
substances, on GSTP1 expression. In the case of the drugs in this study, it has been shown that 
CDDP is detoxified by GSTs (Goto et al., 1999), however for both CDDP and 5-FU, more studies 
on the effects of these drugs on GSTP1 gene expression are needed. The majority of research is 
directed toward associations of GST polymorphisms with cancer incidence and prognosis 
(Goekkurt et al., 2006; McIlwain et al., 2006; Dhawan et al., 2013; Lai et al., 2013) and not the 
direct influence of these drugs on the expression levels of GSTP1, which has a significant clinical 
impact on patient response.  
1.5 Aims and objectives  
 
Determining the effects of commonly-used drugs on the critically important DMEs is of great 
relevance. The aim of this study was to investigate the role of the chemotherapeutic drugs 5-FU 
and CDDP in the differential expression of four DME genes, CYP1A1, 1A2, 1B1 and GSTP1, using 
BP as a model CYP-inducer and a positive control for induction of CYP expression, in an 
oesophageal cancer cell line. This is an important study since most chemotherapeutic drugs have 
on average 30% success rate, and oesophageal cancer is the sixth most common cause of cancer 
deaths globally. To the best of our knowledge, no studies have looked at the effects of 5-FU, 
CDDP and the combinatorial effects of BP and 5-FU, and of BP and CDDP, on the CYP1 and 
GSTP1 genes in oesophageal cancer cells. This study will provide baseline information for future 
pharmacogenetic research, whereby the effects observed in this study may be evaluated in other 
tumour cell lines. The aims of this project will be met by the following objectives: 
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 To investigate the effects of treating the human oesophageal cancer cell line WHCO1 with 
chemotherapeutic drugs 5-FU and CDDP, as well as the CYP-inducer BP.  
 To analyse the morphological changes in the cancer cells in response to treatment, using 
light microscopy. 
 To analyse mRNA and protein expression of the DME genes CYP1A1, CYP1A2, CYP1B1 






















2. MATERIALS AND METHODS 
 
2.1 Cell Culture 
 
2.1.1 Cell line and media 
 
The WHCO1 cell line, originally established from surgical biopsies of primary oesophageal 
squamous cell carcinoma in South Africa (Veale and Thornley, 1994) were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Sigma-Aldrich, USA) containing 10% foetal calf serum 
(Biochrom, Germany), 1% penicillin-streptomycin (Sigma-Aldrich, USA) and 1% GlutaMAX™ 
(Life Technologies, UK), at 37 ºC in a humidified atmosphere of 5% CO2.  
Cryovials containing cells in freezing medium (Appendix A) were removed from liquid nitrogen 
storage and thawed for 2 minutes in a 37 ºC water bath. The vial contents were then transferred 
into a 10 cm tissue culture dish containing 10 mL of DMEM, previously warmed to 37 ºC in the 
water bath. The dish was agitated gently and then incubated at 37 ºC.  
2.1.2 Sub-culturing 
 
Cells were sub-cultured when they reached ~80% confluency, and 10X trypsin-EDTA was 
purchased from Sigma-Aldrich (USA). The culture dish was removed from the incubator and 
media suctioned off. The remaining medium was washed off using 5 mL 1X PBS (Appendix A) 
and thereafter the cells were lifted by adding 5 mL of 1X trypsin-EDTA (Appendix A) and 
incubating at 37 ºC for 7-10 minutes or until the cells were detached from the base of the plate. 
Thereafter the trypsin was inactivated by the addition of 5 mL of culture medium, and the cell 
resuspension was transferred to a 15 mL tube and pelleted by centrifugation at 1000 rpm for 3 
minutes. Following the removal of the supernatant by suction, the pellet was resuspended in 6 mL 






Following trypsinisation and pelleting of cells as described above, the pellet was resuspended in 6 
mL of complete DMEM and the cells were counted using a haemocytometer. Pre-chilled freezing 
medium was added to the cells to reach a final concentration of 1 X 10
6
 cells/mL and mixed gently. 
The suspension was aliquoted 1 mL per cryovial and the vials were slow-cooled to -80º C 
overnight. Thereafter, the vials were transferred into a liquid nitrogen tank for long-term storage.  
2.1.4 Mycoplasma testing  
 
In order to ensure that the growth of any Mycoplasma contaminants being suppressed by the 
antibiotics could be detected, the WHCO1 cells were grown on a sterile glass cover slip in 2 mL 
antibiotic-free medium, in a 35 mm tissue culture dish for at least 48 hours or to ~60% confluence. 
Without removing the growth medium, 1 ml of fixing solution (Appendix A) was added to the cells 
and incubated for a few seconds. The fixing solution was removed, and the incubation and removal 
of fixing solution repeated in the same manner. The cells were then washed several times with 
sterile dH2O to ensure complete removal of any residual fixative, and left to dry by inverting the 
dish. This was followed by staining of the cells for 30 seconds with 500 µL of 0.5 µg/mL Hoechst 
solution (Sigma-Aldrich, USA). The stain was washed off with dH2O and the cover slip placed 
face down onto a microscope slide with a drop of mounting fluid. The cells were visualised using 
fluorescent microscopy. 
2.2 Cell Treatments 
 
2.2.1 MTT assay  
 
This assay was performed to determine the IC50 value, i.e. the concentration of drug required to kill 
50% of the cells in a specific cell line, for 5-FU. Cells were seeded in a 96-well plate at 5 X 10
3
 
cells in a final volume of 90 µL culture medium per well. After 24 hours, the cells were treated 
with 5-FU at a concentration gradient (0; 0.5; 1; 5; 10; 20; 50 and 100 µM) and each concentration 
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was done in triplicate. The control wells (0 µM 5-FU) contained a final concentration of 0.4% 
dimethyl sulphoxide (DMSO) (Sigma-Aldrich, USA), which is representative of the DMSO 
concentration in all the wells, because DMSO was the diluent used to dissolve 5-FU. After an 
incubation period of 24 hours, 10 µL of MTT reagent (Appendix A) was added to each well, 
followed by a further 4 hours of incubation at 37 ºC. Thereafter 200 µL of solubilisation reagent 
(Appendix A) was added to each well and the plate was left in the 37 ºC incubator overnight. The 
spectrophotometric absorbance (OD) of the samples was measured at 595 nm using a microtiter 
plate reader and these values were used to calculate the IC50 of 5-FU for WHCO1 cells using 
GraphPad PRISM
®
 v 5.0 software. 
2.2.2 Cell treatment 
 
The 5-FU, CDDP and BP used for cell treatments were all purchased from Sigma-Aldrich (USA). 
The WHCO1 cells were seeded in 6 cm dishes at 5 X 10
5
 cells/well in 5 mL of DMEM and 
allowed to adhere. The cell culture medium was replaced with serum-free DMEM 16 hours prior to 
the start of treatment. These cell treatments involved the addition of one of the following reagents 
at concentrations determined either through the MTT assay (IC50 determination) or the literature: 
0.2 µM 5-FU; 10 µM BP, a combination of 0.2 µM 5-FU and 10 µM BP; and 0.04% DMSO for 
the control, as this was the maximum concentration of DMSO present at the IC50 concentrations 
used. For the CDDP treatment, the experiment was performed in the same manner except with 9.2 
µM CDDP instead of the 5-FU. The treatments were carried out for 6, 12 and 24 hours.  
2.2.3 Microscopy 
 
The morphology of the cells were observed and photographed subsequent to exposure to chemical 







2.3 Quantitative-Real time PCR 
 
2.3.1 RNA isolation 
 
Prior to RNA isolation, all plasticware and glassware to be used for the isolation were treated with 
DEPC to reduce the likelihood of degradation by RNAses. Buffers and solutions were made up 
with DEPC-treated sterile dH2O (Appendix A). Total RNA was isolated from the cells using the 
Roche High Pure RNA Isolation kit (Germany) as per the manufacturer’s instructions. Briefly, the 
cells were trypsinised and pelleted by centrifugation, and then resuspended in 200 µL 1X PBS. To 
this cell suspension, 400 µL lysis/binding buffer was added and the solution vortexed for 15 
seconds. The entire sample was transferred to a High Pure filter tube inserted into a collection tube, 
then centrifuged for 15 seconds. All centrifugation steps were carried out at 10 000 rpm. Next, the 
flow-through was discarded and a buffer containing DNase I was applied to the sample-bound 
membrane and incubated at room temperature for 15 minutes. Thereafter, the membrane was 
washed with 500 µL of wash buffer I and II subsequently, followed by a final wash with 200 µL 
wash buffer II. The RNA was eluted by centrifugation in 60 µL of elution buffer in a new sterile 
collection tube. All RNA samples were quantified using the NanoDrop
®
 ND-1000 
Spectrophotometer (Inqaba Biotec, South Africa) and the 260/280 and 260/230 ratios noted as a 
measure of sample purity. The samples were stored at -80 ºC until used. 
2.3.2 RNA integrity using agarose gel electrophoresis 
 
To verify the integrity of the RNA, 1 µg of each RNA sample was prepared in DEPC-treated 
sterile RNase-free dH2O with 2X RNA loading buffer (Appendix A) in a total volume of 30 µL. 
The samples were denatured by heating at 55 ºC for 5 minutes, prior to loading onto a 1% agarose 
gel containing ethidium bromide (0.5 µg/mL) in a previously bleach-treated tank using 1X TBE 
(Appendix A) as running buffer. The gel was electrophoresed at 60 V/cm for 1 hour, and visualised 
with a UV-transilluminator.  
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2.3.3 Synthesis of cDNA 
 
First strand cDNA was synthesised using 1 µg total RNA and the Maxima H Minus First Strand 
cDNA Synthesis kit (Thermo Scientific, USA) according to the manufacturer’s instructions. Table 
2.1 shows the components that were added to a sterile nuclease-free tube on ice. Prior to the 
addition of 5X RT buffer and  RevertAid™ Premium Enzyme Mix the mixture was mixed by 
gentle pipetting, centrifuged briefly and incubated at 65 ºC for 5 minutes. Thereafter the samples 
were chilled on ice for a further 5 minutes, centrifuged again and placed on ice. The final 
components were then added to the tube on ice. 
Table 2.1 Components of the Maxima H Minus First Strand cDNA Synthesis kit  
Component Volume (µL) 
1 µg Total RNA x  
25 pmol Oligo(dT)18 primer 0.25  
25 pmol Random hexamer primer 0.25  
10 mM dNTP mix 1  
Nuclease-free dH2O to 15  
5X RT buffer 4 
RevertAid™ Premium Enzyme Mix 1 
Total volume 20 
     
The samples were mixed again by gentle pipetting, centrifuged briefly and incubated for 10 
minutes at 25 ºC followed by 15 minutes at 50 ºC. The reaction was terminated by heating at 85 ºC 








2.3.4 Quantitative real time PCR 
 
Primer sequences and product sizes are listed in Table 2.2. The glyceraldehyde-3-phosphate 
(GAPDH) gene was used as an internal control in the quantitative real-time PCR (qRT-PCR) 
reactions. Primer specificity was verified by the BLAST program (http://www.ncbi.nlm.nih.gov).  
Table 2.2 Primers used in quantitative real-time PCR. 
Target 
gene 






392 Huang et al., 1996 
CYP1A2 F:AACAAGGGACACAACGCTGAAT 
R :GGAAGAGAAACAAGGGCTGAGT 










72 Joshi et al., 2005 
GAPDH F:GCCTGCTTCACCACCTTC 
R:GGCTCTCCAGAACATCATCC 
192 Van Rooyen et al., 2013 
 
The qRT-PCR reaction was performed in a 96-well plate format and each sample was done in 
triplicate, using the SYBR FAST Universal qRT-PCR kit from KAPA Biosystems (South Africa). 






Table 2.3 Components of the qRT-PCR reaction 
Component Volume (µL) 
cDNA 1 
1 µM Forward primer  0.2 
1 µM Reverse primer 0.2 
2X SYBR FAST mix 5 
Sterile dH2O  3.6 
Total volume 10 
 
The reaction was carried out by the Roche Lightcycler 480 II, and the conditions were as follows: 
95 ºC: 3 minutes (pre-incubation) 
95 ºC: 10 seconds 
62 ºC: 20 seconds 40 cycles 
72 ºC: 5 seconds 
 
For all experiments, qRT-PCR data were analysed using the comparative critical threshold (Ct) 
method, whereby the amount of gene of interest was normalised to the amount of housekeeping 
gene (GAPDH) and expressed as fold induction, relative to the mean value of control samples 
using the equation 2
-∆∆Ct
 (Hundley et al., 2006).  
2.3.4.1 Specificity of qRT-PCR primers 
 
The specificity of the primers was verified by analysis of the melting peaks generated after the 
qRT-PCR reaction, as well as both agarose gel electrophoresis and cycle sequencing of the qRT-





2.3.4.2 Cycle sequencing 
 
First, clean-up of qRT-PCR products was set up as shown in Table 2.4, in order to remove excess 
primer as well as unincorporated ddNTPs. The shrimp alkaline phosphatase and exonuclease I 
enzymes were purchased from Thermo Scientific, USA. The reaction tubes were incubated at      
37 ºC for 1 hour, and then at 75 ºC for 15 minutes. 
Table 2.4 Components of the qRT-PCR clean-up reaction 
Component Volume (µL) 
qRT-PCR product 5 
Shrimp-alkaline phosphatase 1 
Exonuclease I 0.1 
Nuclease-free dH2O 13.9 
Total volume 20 
 
Thereafter, the cycle sequencing reaction was prepared using the ABI Prism
®
 BigDye™ 
Terminator v3.1 kit (Applied Biosystems, USA), as per the manufacturer’s instructions. Briefly, 
the components of the kit were set up for each primer (forward and reverse) as shown in Table 2.5. 
Table 2.5 Components of the cycle sequencing reaction 
Component Volume (µL) 
10 pm Primer (either forward or reverse) 1 
qRT-PCR product (post-clean-up) 1 
1X Sequencing buffer 2 
0.5X Terminator mix 1 
Nuclease-free dH2O 5 
Total volume 10 
 
The cycle sequencing reaction was performed using the Bio-Rad T100™ Thermal Cycler, under 
the following conditions: 
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98 ºC: 5 minutes (pre-incubation) 
96 ºC: 10 seconds 
50 ºC: 15 seconds 30 cycles 
60 ºC: 4 minutes 
 
Thereafter, a further clean-up step as well precipitation of the sequencing product was required. 
Firstly, 22 µL absolute ethanol and 1 µL 5 M sodium oxaloacetate (pH 4.5) was added to each 
cycle sequencing product, followed by brief mixing and storage at -20 ºC for 2 hours. The samples 
were centrifuged at 10 000 rpm for 5 minutes and the supernatant decanted. Next, 40 µL 70% 
ethanol was added and the samples were centrifuged for another 5 minutes. Once the supernatant 
was discarded, the samples were left to air-dry for 1 hour at room temperature. The sequencing 
products were resuspended in 10 µL sterile dH2O and half of each sample was aliquoted into the 
wells of a 96-well plate, followed by the addition of 5 µL Hi-Di™ Formamide (Applied 
Biosystems, USA) to each well. The samples were analysed on an ABI 3130xl Genetic Analyzer 
(Applied Biosystems, USA), and computational analysis of the results was performed using the 
BioEdit Sequence Alignment Editor v 7.0.0 (Tom Hall, Isis Pharmaceuticals Inc.). To verify the 
specificity of the sequences, the online BLAST tool (http://www.ncbi.nlm.nih.gov) was utilised. 
2.4 Western blot analysis 
 
2.4.1 Isolation of total soluble protein 
 
10X RIPA buffer and protease inhibitor cocktail were purchased from Cell Signalling Technology
®
 
(USA) and Roche (Germany), respectively. The culture dishes were placed in ice, the culture 
medium was suctioned off and excess medium was washed off using ice-cold sterile 1X PBS. The 
cells were then scraped off the dish in 1X RIPA buffer containing protease inhibitor cocktail 
(Appendix A).  The lysate was transferred to a sterile 1.5 mL tube and incubated on ice for 30 
minutes, prior to centrifugation at 13 000 rpm for 20 minutes at 4 ºC to pellet the cell debris. Next, 
the supernatant containing the total soluble proteins was transferred into a new tube and stored at   
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-20 ºC until use. Aliquots were used for protein quantification using the BCA Protein 
Quantification kit (Thermo Scientific, USA), according to the manufacturer’s instructions. 
2.4.2 SDS-PAGE 
 
A 1.5 mm thick 8-12% resolving gel (Appendix A) and a 5% stacking gel (Appendix A) were 
prepared in a Bio-Rad Mini PROTEAN
©
 3 casting apparatus as per the manufacturer’s 
instructions. Table 2.6 shows the protein sample preparation components and volumes. Samples 
were denatured by heating at 95 ºC for 10 minutes before loading.  
Table 2.6 Components of the protein sample preparation tubes for SDS-PAGE  
Component Volume (µL) 
20 µg protein x 
5X SDS loading buffer 6 
100 mM dTT 1 
1X RIPA buffer  1 
Nuclease-free dH2O to 35 
 
The prepared gel was placed into a Bio-Rad running tank containing 1X running buffer (Appendix 
A). The samples were loaded into the wells, as well as 5 µL of the PageRuler™ Prestained Protein 
Ladder (Thermo Scientific, Europe).  The apparatus was connected to the Bio-Rad Power pack 200 
and the gel was electrophoresed at 100 V/cm for 75 minutes. 
 
2.4.3 Protein transfer onto nitrocellulose membrane 
 
The 1X transfer buffer (Appendix A) was prepared prior to the transfer and chilled at 4 °C. A 
Hybond-ECL membrane (Amersham Biosciences, UK) was cut to match the gel size and left to 
soak in the transfer buffer for at least 15 minutes. After completion of electrophoresis, the stacking 
gel was removed and the resolving gel containing the separated proteins was assembled under 
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transfer buffer into a “sandwich” as indicated in the diagram below (Figure 2.1) and placed within 









The cassette was then placed into the transfer unit of the Bio-Rad Mini PROTEAN
©
 3 transfer tank 
containing transfer buffer. An ice pack was placed in the tank to prevent over-heating.  The transfer 
apparatus was connected to the Bio-Rad Powerpack 200 and protein transfer took place at 100 V 
for 90 minutes. 
2.4.4 Antibody incubation and western blot detection 
 
The primary antibodies used were as follows: goat polyclonal IgG CYP1A1 (sc-9828), mouse 
monoclonal IgG CYP1A2 (sc-53241) and rabbit polyclonal IgG CYP1B1 (sc-32882) from Santa 
Cruz Technologies (Europe); rabbit polyclonal IgG GSTP1 (AB8902) from Merck Millipore 
(Germany); and rabbit anti-p38 MAP kinase IgG (MO800) from Sigma-Aldrich (Germany). The 
secondary antibodies used were blotting grade affinity purified goat anti-mouse IgG horseradish 
peroxidase (HRP) conjugate (170-6516) and goat anti-rabbit IgG HRP conjugate (170-6515) (Bio-
Rad, USA) as well as donkey anti-goat IgG HRP conjugate (Santa Cruz Technologies, Europe). 
The antibody dilutions used are listed in Table 2.7. 
Figure 2.1 Diagram illustrating the assembling of a protein transfer sandwich. (Adapted 
with modification from http://www.bio-rad.com/en-id/product/trans-blot-cell) 
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Table 2.7 Antibody dilutions used for western blot analysis. 
 
After the transfer was completed the membrane was removed from the sandwich and washed twice 
with 1X PBS containing 0.1% Tween-20 (PBST, Appendix A) and then blocked with 5% fat-free 
milk in PBST (Appendix A) for 1 hour at room temperature, with gentle shaking. After blocking, 
the membranes were incubated with primary antibody, diluted to the desired concentration in 
blocking solution. This incubation was done overnight at 4 ºC, with gentle shaking. The next day 
the membrane was washed in PBST (2 X 10 minutes followed by 2 X 5 minute washes) and 
incubated with the appropriate HRP-conjugated secondary antibody in blocking solution, for 2 
hours at room temperature with gentle shaking. The membrane was then washed as before in PBST 
and visualised by enhanced chemiluminescence using the Bio-Rad Clarity Western ECL Substrate 
(Thermo Scientific, Europe) as per the manufacturer’s instructions.  Membranes were exposed to 
x-ray film and the resulting chemiluminescent signal captured by developing and fixing the film.  
To strip the antibody from the blot, the stripping buffer (Appendix A) was warmed to 50 ºC and the 
blot was incubated in the buffer at 50 ºC for 30 minutes, with brief agitation every 10 minutes. 
Thereafter, the membrane was washed twice for 10 minutes each with PBST. Each blot was then 
reused from the blocking stage as described previously, in order to detect the internal loading 
control protein p38. For analysis of the western blots, the x-ray films were scanned and the 
intensity of the protein bands quantified and normalised to p38 using Image Studio Lite software. 
Each western blot was performed twice to confirm reproducibility of the results. 
 
Protein Primary antibody dilution Secondary antibody dilution 
CYP1A1 1:2000 1:3000 (goat anti-mouse) 
CYP1A2 1:1000 1:3000 (goat anti-mouse) 





1:5000 (donkey anti-goat) 





The findings of the study are reported in the sections below.  
3.1 WHCO1 cells tested negative for Mycoplasma  
 
The Mycoplasmas constitute a large group of prokaryotic organism that are resistant to most 
antibiotics used in tissue culture laboratories and frequently contaminate cell cultures. It is 
important to test for these organisms because although they can easily go undetected, their 
presence can alter numerous cell functions and characteristics, including cell growth rate and 
morphology, thus affecting experimental data derived from infected cells (Garner et al., 2000; 
Drexler and Uphoff, 2002). WHCO1 cells were regularly tested for Mycoplasma infection using a 
method based on Hoechst DNA staining (see section 2.1.4) and the cells were visualised using 
fluorescent microscopy. Aside from the nuclei of the WHCO1 cells, no other fluorescent bodies 
could be observed which indicates that the cells were Mycoplasma-negative (Figure 3.1). Infected 
cells would exhibit fluorescing nuclei as well as extra-nuclear fluorescence of Mycoplasma DNA 























3.2 Effects of 5-FU and BP on WHCO1 cells 
 
3.2.1 An IC50 of 0.2 µM 5-FU was obtained in WHCO1 cells 
 
For drug treatment experiments, a fixed concentration of each drug was required; thus, an IC50 for 
each drug was calculated or obtained from literature. The MTT cell proliferation assay was used to 
do this and the methodology is described in section 2.2.1. Resultant assay data analysis was done 
using GraphPad PRISM® v 5.0 software to generate a sigmoidal dose-response curve as shown in 
Figure 3.2. The details on how the software calculates the IC50 value from this curve are given in 
Appendix B (Figure B1). The IC50 value for 5-FU was calculated to be 0.2 µM and this 
concentration was used for all subsequent 5-FU treatments. However, after completion of this set 
of experiments, a publication by Kaschula et al. (2012) reported an IC50 for 5-FU in WHCO1 cells 
of 7.9 µM, which is different to what was observed in this study. This is a cause for concern and 
further studies are needed to confirm the cause of this variation, but likely reasons are a difference 





Figure 3.1 Fluorescent microscopy image showing Hoechst-stained cell cultures for 
Mycoplasma testing. WHCO1 cells tested negative for Mycoplasma with only nuclear staining (arrow 












3.2.2 Co-treatment of WHCO1 cells with 5-FU and BP induced early apoptosis  
 
The morphology of WHCO1 cells was observed and photographed subsequent to exposure to all 
drug treatments, using a light microscope (Figure 3.3). The concentration of BP used to treat cells 
was obtained from the literature (Plant et al., 1985; Barhoumi et al., 2000). No morphological 
changes were observed when 5-FU and BP were used alone, however, at 24 hours, blebbing of the 
cell membranes was observed in less than 1% of the cells when a combination of 5-FU and BP was 







Figure 3.2 Sigmoidal dose-response curve for 24 hour 5-FU treatment of WHCO1 cells. The 
































Figure 3.3 Light microscopy images showing 
WHCO1 cell morphology in response to 5-FU/BP 
treatment. All images shown were taken after 24 hours of 
treatment. Blebbing of the cell membrane was observed in the 
cells treated with 5-FU and BP together (shown by the arrow), 
which is an indicator of apoptosis. Photograph A (right) is an 
enlarged image of these apoptotic cells. Control cells were 
treated with 0.04% DMSO. 
 
Control + 5-FU 







3.2.3 Co-treatment of WHCO1 cells with CDDP and BP induced early apoptosis 
 
A concentration of 9.2 µM CDDP was used to treat the WHCO1 cells since the literature reports 
this concentration to be the IC50 for CDDP in this cell line (Kaschula et al., 2012). Similar to the  
5-FU and BP co-treatment, CDDP and BP in combination also induced blebbing of the WHCO1 
cell surfaces in less than 1% of the cells and this was noticed after 24 hours, indicating early stage 


















Figure 3.4 Light microscopy images showing 
WHCO1 cell morphology in response to 
CDDP/BP treatment. All images shown were 
taken after 24 hours of treatment. Blebbing of the cell 
membrane was observed in the cells treated with 
CDDP and BP together (shown by the arrow), which 
is an indicator of apoptosis. Photograph A (right) is 
an enlarged image of these apoptotic cells. Control 
cells were treated with 0.04% DMSO. 
 
A 
Control + CDDP 
+ BP + CDDP + BP 
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3.3 RNA extraction and qRT-PCR 
 
3.3.1 The extracted RNA was suitable for cDNA synthesis 
 
In order to determine the gene expression profiles associated with observed changes when 
undertaking cell culture experiments, qRT-PCR was performed, which requires the extraction of 
RNA. The quality of the RNA must be validated to ensure that the downstream experiments, i.e. 
cDNA synthesis and qRT-PCR, yield results that are as accurate as possible and not influenced by 
poor quality of RNA. For each treatment, the overall quality and integrity of the extracted RNA 
was verified by electrophoresis on an agarose gel. Figure 3.5 shows an example of a gel where the 
RNA samples showed acceptable overall quality and integrity; sharp 28S and 18S ribosomal RNA 
bands, with no low molecular weight smears. Furthermore, the amount and purity of the RNA 
samples were validated by spectrophotometry, where all samples used had 260/280 and 260/230 











Figure 3.5 Validation of overall RNA quality and integrity by agarose gel electrophoresis. Sharp 28S 








3.3.2 The primers for CYP1A1, 1A2, 1B1, GSTP1 and GAPDH were specific  
 
When performing qRT-PCR, it is vital to ensure that the primers used amplify only the desired 
product, and no other non-specific products, and that no primer dimers are formed. One method of 
verifying this is through melt curve analysis. The melt curve is also referred to as a dissociation 
curve and provides a measurement of the temperature at which 50% of the double-stranded DNA 
molecules are dissociated into single strands, which is quantified by the fluorescence of the DNA-
intercalating dye in the reaction, such as SYBR green. The melting temperature is unique to the 
qRT-PCR product, which means that a single peak shows amplification of a single product, whilst 
multiple different peaks are indicative of co-amplification of extra products. Smaller additional 
peaks can also indicate the presence of primer dimers. The three identical peaks observed for each 
product in the melt curves generated by each primer pair were indicative of a single product (in 
triplicate), with no primer dimers. An example of the melt curve for CYP1B1 is shown in Figure 
3.6, and an example for each of the other target genes (including GAPDH) is shown in Appendix C 







Figure 3.6 Melt curve for CYP1B1 product after qRT-PCR. Three matched peaks can be observed, 
indicating that the primers amplified a single product (in triplicate), in this case, CYP1B1, and confirming that no 




Additionally, the amplification of a single product of the correct size for each primer pair 
(including GAPDH) was verified by agarose gel electrophoresis of the sample after qRT PCR, as 
shown in Appendix D (Figure D1). Furthermore, the qRT-PCR products were sequenced and the 
online BLAST tool (http://www.ncbi.nlm.nih.gov) was used for confirmation (data not shown).  
 
3.4 The effects of 5-FU, CDDP and BP on the mRNA and protein expression of CYP1A1, 
CYP1A2, CYP1B1 and GSTP1 
 
The main aim of this study was to investigate the effects of chemotherapeutic drug treatment (5-FU 
and CDDP) alone and in the presence of BP, on the WHCO1 cancer cell line by evaluating changes 
in mRNA and protein expression of four DMEs (CYP1A1, 1A2, 1B1 and GSTP1).  This was 
achieved using qRT-PCR and western blot analyses and the results are shown below. For each 
experiment, cells were treated for 6, 12 and 24 hours. All qRT-PCR data are represented as fold 
induction relative to the control samples (treated with DMSO only), after normalisation to the 
housekeeping gene GAPDH. The result obtained for the control in each qRT-PCR experiment was 
taken as the reference and represented as having a fold expression of one, thus any bars above one 
indicate an increase in gene expression whilst those below one indicate a decrease in gene 
expression, relative to the control. All densitometric analyses of western blots were performed 
using LI-COR
® 
Image Studio Lite software v 3.1.4 and are represented as the ratio of the amount 
of DME protein detected to the amount of loading control protein (p38) detected. As was the case 
with the qRT-PCR results, the result obtained for the control (i.e. DMSO-only treatment) in each 
western blot experiment was taken as the point of reference and represented as having a fold 






3.4.1 CYP1A1 mRNA expression was significantly induced by 5-FU 
 
The treatment of the WHCO1 cells with 5-FU triggered small but significant and reproducible 
increases in CYP1A1 mRNA expression in comparison with the control, with a maximal increase 
of ~2-fold at 24 hours. As expected, exposure to BP resulted in robust increases in CYP1A1 mRNA 
of 6-fold, 9-fold and 11-fold CYP1A1 expression at 6, 12 and 24 hour respectively (Figure 3.7). 
The induction in response to BP was also observed at the protein level at 12 hours (20-fold) and 
more readily at 24 hours (70-fold, Figure 3.8). When cells were treated with a combination of 5-FU 
and BP, a response similar to what was observed for the BP only treatment was produced at 6 and 
12 hours (~6-fold and ~9-fold, respectively). However, at 24 hours, the increase was not as large, 
with a 4-fold induction of CYP1A1 mRNA. The protein expression trend was similar at 24 hours; 
whilst BP exposure alone led to a 70-fold increase in CYP1A1 protein compared to the control, BP 
and 5-FU combined resulted in just a 40-fold increase in expression, compared to the control, as 























































































6 hrs 12 hrs 24 hrs 
Figure 3.8 CYP1A1 protein expression in response to 5-FU and/or BP treatment. Cells 
were treated with 5-FU, BP and 5-FU + BP in combination. Control cells were treated with 0.04% 
DMSO. The bands shown (lower panel) were obtained by western blot analysis using the CYP1A1 
antibody and the p38 antibody (loading control), and the corresponding bar graph derived from 
densitometric analyses of the western blots (upper panel) represents the expression level of CYP1A1 
protein normalised to the internal loading control protein p38. 
Figure 3.7 CYP1A1 mRNA expression in response to 5-FU and/or BP treatment. Cells were 
treated with 5-FU, BP and 5-FU + BP in combination. Control cells were treated with 0.04% DMSO and 
all control mRNA expression levels are represented as one. The bar graph represents mRNA expression 
derived from qRT-PCR data and the fold changes are in reference to the control which has been 
normalised to one. The data are representative of three independent experiments. The * indicates 
significant differences (p ≤ 0.05) compared to control cells. 
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3.4.2 CYP1A2 mRNA expression was differentially altered by 5-FU 
 
Unlike what was observed for CYP1A1, no significant difference was observed with respect to 
CYP1A2 mRNA expression after 5-FU treatment at 6 hours, however, a significant decrease (0.5- 
fold) was noted at the 12 hour time point, while a significant increase was observed at 24 hours 
(~2-fold). Similar to CYP1A1, and as expected, BP alone resulted in much more pronounced 
CYP1A2 mRNA and protein induction, especially at 12 and 24 hours: for mRNA expression, a 
1.5-fold, 4-fold and 8-fold induction was observed at 6, 12 and 24 hours respectively, and for 
protein induction, a ~5-fold, ~20-fold and ~90-fold was observed (Figure 3.9). At 6 hours, contrary 
to CYP1A1, the combination of 5-FU and BP led to much more enhanced expression of CYP1A2, 
compared to when treated with BP alone.  But the effect observed at 24 hours with the combination 
treatment was similar to that observed for CYP1A1, where the increase was not as large (~5-fold) 














































































Figure 3.9 CYP1A2 mRNA expression in response to 5-FU and/or BP treatment. Cells 
were treated with 5-FU, BP and 5-FU + BP in combination. Control cells were treated with 0.04% 
DMSO and all control mRNA expression levels are represented as one. The bar graph represents 
mRNA expression derived from qRT-PCR data and the fold changes are in reference to the control 
which has been normalised to one. The data are representative of three independent experiments. The 
* indicates significant differences (p ≤ 0.05) compared to control cells. 
Figure 3.10 CYP1A2 protein expression in response to 5-FU and/or BP treatment. Cells were 
treated with 5-FU, BP and 5-FU + BP in combination. Control cells were treated with 0.04% DMSO. The 
bands shown (lower panel) were obtained by western blot analysis using the CYP1A2 antibody and the p38 
antibody (loading control), and the corresponding bar graph derived from densitometric analyses of the 
western blots (upper panel) represents the expression level of CYP1A2 protein normalised to the internal 
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3.4.3 CYP1B1 mRNA was significantly induced by 5-FU 
 
The expression of CYP1B1 mRNA in WHCO1 cells treated with 5-FU was significantly increased, 
although at a low scale (Figure 3.11) which follows the trend observed for CYP1A1. A 1.4, 1.7 and 
1.6-fold increase in mRNA expression was observed at 6, 12 and 24 hours respectively, while also 
similar to CYP1A1, no protein expression could be detected at these time points and under these 
treatment conditions, relative to the controls (Figure 3.12). Treatment with BP led to significant 
increases in both mRNA and protein expressions; an average increase of 8-fold in mRNA 
expression was observed at all three time points, while a ~40-fold, ~60-fold and ~70-fold increase 
in protein expression throughout the time points was observed. When the cells were co-treated with 
BP and 5-FU, CYP1B1 mRNA expression steadily increased from ~1.3-fold at 6 hours, to ~5-fold 
at 12 hours, to ~9-fold at 24 hours, as shown in Figure 3.11. This pattern was reflected in the 
protein (Figure 3.12). However, it is interesting to note that at 6 and 12 hours, the extent of 
CYP1B1 mRNA inductions were much reduced compared to induction with BP alone, which was 
also reflected at the protein level (at 6 hours).  At 24 hours, both BP and BP + 5-FU induction was 












































































Figure 3.11 CYP1B1 expression in response to 5-FU and/or BP treatment. Cells were treated with 5-
FU, BP and 5-FU + BP in combination. Control cells were treated with 0.04% DMSO and all control mRNA 
expression levels are represented as one. The bar graph represents mRNA expression derived from qRT-PCR data 
and the fold changes are in reference to the control which has been normalised to one. The data are representative 
of three independent experiments. The * indicates significant differences (p ≤ 0.05) compared to control cells. 
Figure 3.12 CYP1B1 protein expression in response to 5-FU and/or BP treatment. Cells were 
treated with 5-FU, BP and 5-FU + BP in combination. Control cells were treated with 0.04% DMSO. The bands 
shown (lower panel) were obtained by western blot analysis using the CYP1B1 antibody and the p38 antibody 
(loading control), and the corresponding bar graph derived from densitometric analyses of the western blots 










3.4.4 GSTP1 mRNA expression was significantly decreased by 5-FU 
 
Exposure to 5-FU led to small but significant decreases in GSTP1 mRNA expression, namely ~0.2-
fold decreases throughout the time points (Figure 3.13). BP exposure did not lead to induction of 
GSTP1 mRNA at 6 hours, but there was a significant increase at 12 hours (1.4-fold) and a 
significant decrease at 24 hours (~0.6-fold). Furthermore, treatment of the WHCO1 cells with 5-
FU and BP combined did not cause any significant changes in mRNA expression at the early time 
points, although a slight but significant increase, 1.2-fold compared to the control, was observed at 
24 hours. The pattern of GSTP1 protein expression generally did not follow that of the mRNA, and 




































































































Figure 3.13 GSTP1 gene expression in response to 5-FU and/or BP treatment. Cells were 
treated with 5-FU, BP and 5-FU + BP in combination. Control cells were treated with 0.04% DMSO and 
all control mRNA expression levels are represented as one. The bar graph represents mRNA expression 
derived from qRT-PCR data and the fold changes are in reference to the control which has been normalised 
to one. The data are representative of three independent experiments. The * indicates significant 
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Figure 3.14 GSTP1 protein expression in response to 5-FU and/or BP treatment. Cells were 
treated with 5-FU, BP and 5-FU + BP in combination. Control cells were treated with 0.04% DMSO. The 
bands shown (lower panel) were obtained by western blot analysis using the GSTP1 antibody and the p38 
antibody (loading control), and the corresponding bar graph derived from densitometric analyses of the 
western blots (upper panel) represents the expression level of GSTP1 protein normalised to the internal loading 
control protein p38. 
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The mRNA and protein expression changes of the four DMEs in response to the 5-FU and/or BP 
treatments, as well as the morphological changes observed in the WHCO1 cells, are summarised in 
Table 3.1. 
 
Table 3.1 Summary of findings on the WHCO1 cells when treated with 5-FU, BP and 5-
FU+BP. The fold changes of the significant increases and decreases in expression are given in parentheses.  
 5-FU BP 5-FU + BP 
6 hrs 12 hrs 24 hrs 6 hrs 12 hrs 24 hrs 6 hrs 12 hrs 24 hrs 
Effects on morphology when compared to untreated control 
 None None None None None None None None Blebbing 
(< 1% of 
cells) 































































None None Increase 
(1.3) 
Differences in protein expression when compared to untreated control 




















































3.5 The effects of CDDP and BP on the mRNA and protein expression of CYP1A1, CYP1A2, 
CYP1B1 and GSTP1 
 
A second chemotherapeutic drug, CDDP, was also investigated in the same way as was done for  
5-FU. Like 5-FU, CDDP is one of the most commonly used drugs for the treatment of various 
tumours. Below, observations on the work performed using CDDP, BP and the WHCO1 cells are 
presented.  
3.5.1 CYP1A1 mRNA expression was differentially altered by CDDP 
 
The exposure of the WHCO1 cells to CDDP led to minor but significant changes in CYP1A1 
mRNA expression, at 6  (1.3-fold increase) and 12 hours (0.6-fold decrease) but no significant 
difference at 24 hours, compared to the control (Figure 3.15). None of these changes were 
observed in the CYP1A1 protein (Figure 3.16).  CDDP, when used in the presence of BP, caused 
an induction of CYP1A1 at all the three time points, being ~4-fold at 6 hours and ~6-fold at both 12 
and 24 hours (Figure 3.16), although these increases were less than what was observed for BP 
alone at 12 (~12-fold) and 24 hours (~16-fold). For the protein expression, the effect of co-
administration of BP + CDDP was only observed at 12 hours (~40-fold) and expression was less 
detectable at 24 hours (below 10-fold), as shown in Figure 3.16. This effect was similar to that 












































































Figure 3.15 in CYP1A1 gene expression in response to CDDP and/or BP treatment. Cells 
were treated with CDDP, BP and CDDP + BP in combination. Control cells were treated with 0.04% 
DMSO and all control mRNA expression levels are represented as one. The bar graph represents 
mRNA expression derived from qRT-PCR data and the fold changes are in reference to the control 
which has been normalised to one. The data are representative of three independent experiments. The * 
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Figure 3.16 CYP1A1 protein expression in response to CDDP and/or BP treatment. Cells were 
treated with CDDP, BP and CDDP + BP in combination. Control cells were treated with 0.04% DMSO. The 
bands shown (lower panel) were obtained by western blot analysis using the CYP1A1 antibody and the p38 
antibody (loading control), and the corresponding bar graph derived from densitometric analyses of the 
western blots (upper panel) represents the expression level of CYP1A1 protein normalised to the internal 
loading control protein p38. 
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3.5.2 CYP1A2 mRNA expression was significantly decreased by CDDP 
 
CDDP treatment of WHCO1 cells led to a significant down-regulation of CYP1A2 mRNA 
expression throughout the time points (Figure 3.17), with the level of mRNA expression almost 
undetectable at ~0.02 to 0.07-fold (Figure 3.18). The BP + CDDP treatment resulted in increases in 
CYP1A2 mRNA expression at 6, 12 and 24 hours (~2.2-fold, 4-fold and 11-fold respectively, 
compared to the control), as shown in Figure 3.17. This pattern was also not reflected in the 
protein, but interestingly, followed the pattern of expression seen in response to BP treatment; i.e. 
the co-treatment led to a ~5-fold increase in expression at 6 hours, which increased to  ~40-fold at 
12 hours and subsequently decreased to ~7–fold at 24 hours (Figure 3.18). Unlike the ~90-fold 
induction of CYP1A2 protein by BP observed in Figure 3.10, treatment with BP in the CDDP 
experiment led to a protein induction level of only ~14-fold, as shown in Figure 3.18.Similarly to 
CYP1A1, the induction of CYP1A2 mRNA and protein in response to CDDP + BP was lower at 


















































































Figure 3.17 CYP1A2 gene expression in response to CDDP and/or BP treatment. Cells were 
treated with CDDP, BP and CDDP + BP in combination. Control cells were treated with 0.04% DMSO and 
all control mRNA expression levels are represented as one. The bar graph represents mRNA expression 
derived from qRT-PCR data and the fold changes are in reference to the control which has been normalised 
to one. The data are representative of three independent experiments. The * indicates significant 
differences (p ≤ 0.05) compared to control cells. 
Figure 3.18 CYP1A2 protein expression in response to CDDP and/or BP treatment. Cells were 
treated with CDDP, BP and CDDP + BP in combination. Control cells were treated with 0.04% DMSO. The 
bands shown (lower panel) were obtained by western blot analysis using the CYP1A2 antibody and the p38 
antibody (loading control), and the corresponding bar graph derived from densitometric analyses of the western 











3.5.3 CYP1B1 mRNA expression was significantly decreased by CDDP 
 
In response to CDDP treatment, the expression of CYP1B1 mRNA was significantly down-
regulated at 6 (0.7-fold) and 12 hours (0.6-fold), but remained unaffected at 24 hours (Figure 3.19). 
Similarly to the response of CYP1B1 to 5-FU exposure, these changes were not observable at the 
protein level (Figure 3.20). Exposure of the WHCO1 cells to CDDP and BP in combination led to 
a steady increase in mRNA expression, from 8-fold at 6 hours to ~12-fold at 12 hours to ~16-fold 
at 24 hours, compared to the control, which mirrored the trend of induction caused by BP, but was 
higher than the level of induction by BP at 6 and 12 hours. Furthermore, this pattern was detected 
in the CYP1B1 protein, as shown in Figure 3.20, i.e. an 8-fold increase at 6 hours, followed by a 






















































































Figure 3.19 CYP1B1 gene expression in response to CDDP and/or BP treatment. Cells were 
treated with CDDP, BP and CDDP + BP in combination. Control cells were treated with 0.04% DMSO and 
all control mRNA expression levels are represented as one. The bar graph represents mRNA expression 
derived from qRT-PCR data and the fold changes are in reference to the control which has been normalised 
to one. The data are representative of three independent experiments. The * indicates significant differences 
(p ≤ 0.05) compared to control cells. 
Figure 3.20 CYP1B1 protein expression in response to CDDP and/or BP treatment. Cells were 
treated with CDDP, BP and CDDP + BP in combination. Control cells were treated with 0.04% DMSO. The 
bands shown (lower panel) were obtained by western blot analysis using the CYP1B1 antibody and the p38 
antibody (loading control), and the corresponding bar graph derived from densitometric analyses of the 
western blots (upper panel) represents the expression level of CYP1B1 protein normalised to the internal 
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3.5.4 GSTP1 expression was significantly increased by CDDP 
 
In contrast to the response of GSTP1 mRNA to 5-FU, there were small but significant increases in 
GSTP1 mRNA expression in response to CDDP treatment (Figure 3.21), namely 1.3-fold at 6 
hours, 1.2-fold at 12 hours and 1.8-fold at 24 hours, compared to the control. Exposure to BP also 
induced GSTP1 mRNA expression to a minor but significant extent (~1.5-fold) throughout the time 
points. In the case of BP and CDDP combination treatment, there was a significant increase in 
mRNA expression only at 24 hours (1.2-fold) as shown in Figure 3.21, which is similar to the case 
of BP + 5-FU treatment at 24 hours. Also similar to the 5-FU and/or BP experiments, the protein 
expression pattern generally did not follow that of the mRNA expression in response to CDDP, 
where the protein levels exhibited no major or consistent changes compared to the control, and any 




































































































Figure 3.21 GSTP1 gene expression in response to CDDP and/or BP treatment. Cells were 
treated with CDDP, BP and CDDP + BP in combination. Control cells were treated with 0.04% DMSO and 
all control mRNA expression levels are represented as one. The bar graph represents mRNA expression 
derived from qRT-PCR data and the fold changes are in reference to the control which has been normalised 
to one. The data are representative of three independent experiments. The * indicates significant differences 
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Figure 3.22 GSTP1 protein expression in response to CDDP and/or BP treatment. Cells were 
treated with CDDP, BP and CDDP + BP in combination. Control cells were treated with 0.04% DMSO. The 
bands shown (lower panel) were obtained by western blot analysis using the GSTP1 antibody and the p38 
antibody (loading control), and the corresponding bar graph derived from densitometric analyses of the 
western blots (upper panel) represents the expression level of GSTP1 protein normalised to the internal 
loading control protein p38. 
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The mRNA and protein expression changes of the four DMEs in response to the CDDP and/or BP 
treatments, as well as the morphological changes observed in the WHCO1 cells, are summarised in 
Table 3.2. 
Table 3.2 Summary of findings on the WHCO1 cells when treated with CDDP and BP. The 
fold changes of the significant increases and decreases in expression are given in parentheses.  
 CDDP BP CDDP + BP 
6 hrs 12 hrs 24 hrs 6 hrs 12 hrs 24 hrs 6 hrs 12 hrs 24 hrs 
Effects on morphology when compared to untreated control 
 None None None None None None None None Blebbing 
(< 1% of 
cells) 































































None None Increase 
(1.2) 
Differences in protein expression when compared to untreated control 





























































This study examined the effects of two chemotherapeutic drugs, 5-FU and CDDP, as well as the 
known CYP-inducing compound BP, on the expression of four DMEs, CYP1A1, 1A2, 1B1 and 
GSTP1. The results showed mRNA expression changes of various magnitudes i.e. fold changes (as 
summarised in Table 3.1 and Table 3.2). Many studies of this nature declare a certain fold change 
amount as a threshold, below which any changes in gene expression are not considered to be 
biologically meaningful. Early microarray publications considered a 2-fold change a reasonable 
cut-off (DeRisi et al., 1996; Schena et al., 1996), while more recent studies use combination 
criteria to accept genes as differentially expressed, for example only if they show a minimum fold 
change of 1.5 and also satisfy p < 0.05 (Peart et al., 2005; Raouf et al., 2008), or a fold change of 
at least 1.3 and p < 0.2 (Huggins et al., 2008). Whilst the application of this method may appear to 
increase the strength of the findings, the combination criteria are determined ad hoc, thus the 
possibility remains that gene expression changes that are dismissed as not meaningful may in 
reality elicit important physiological changes (McCarthy and Smyth, 2009). In formal statistical 
terms, genes are considered to be differentially expressed when their expression levels change 
between two treatment conditions, irrespective of how small that change may be. Therefore in this 
project, no threshold was applied and any fold change in mRNA expression of the DMEs was 
regarded as potentially physiologically meaningful. The observed mRNA expression changes were 
reproducible amongst three independent cell treatment experiments and the data also had to satisfy 
p < 0.05 for statistical significance. This research serves as a preliminary study; future work may 
confirm this work by repeating it in additional cancer cell lines, and may investigate the biological 
effects of the resulting differential expressions and whether these changes may be extrapolated to 
potential clinical consequences. To the best of our knowledge, this is the first study to explore the 
effects of the two chemotherapeutic drugs on the CYP and GST DMEs in an oesophageal cancer 
cell line. The results will be discussed in detail below. 
Treatment of the WHCO1 cells with 5-FU was associated with increased expression of CYP1A1 
and CYP1B1, which was generally enhanced in the presence of BP. The precise mechanism 
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responsible for the up-regulation caused by 5-FU remains to be elucidated, but given that the AhR 
pathway mediates CYP1 transcription, it is likely that this pathway is involved. To the best of our 
knowledge, a direct link between 5-FU and the AhR pathway has not been established. However, 
previous studies have shown that 5-FU is capable of inducing the activity of cyclin A-cyclin-
dependent kinase 2 (Cdk2), an important cell cycle regulatory protein, in four different human 
cancer cell lines, along with other cyclin proteins (Takeda et al., 1999; Yoshikawa et al., 2001). 
Interestingly, inhibition of the AhR has been found to be associated with down-regulation of cyclin 
and Cdk-2 expression. Thus it is possible that an up-regulation in Cdk2 activity, in this case caused 
by 5-FU, is linked to a corresponding up-regulation in AhR activity ultimately resulting in 
increased CYP1 expression (Abdelrahim et al., 2003; Korzeniewski1 et al., 2010). Alternatively, 5-
FU has also been shown to activate an important pathway known as the NF-E2 p45-regulated 
factor (Nrf2) signalling pathway. The regulatory region of the Nrf2 gene encompasses several 
AhR-binding response elements (Miao et al., 2005; Kohle and Bock, 2007; Hayes and McMahon, 
2009); some studies have suggested that Nrf2 regulates AhR expression and hence modulates 
numerous downstream events of the AhR signalling cascade, including the transcriptional 
regulation of CYP1 genes (Shin et al., 2007). Therefore, it is also plausible that 5-FU increases 
Nrf2 expression and activity, ultimately leading to increased CYP1 expression. Future work could 
begin to determine this by investigating the effects of 5-FU on AhR, Cdk2 and Nrf2 mRNA and 
protein expression levels in the WHCO1 cells. 
The further increase in CYP1A1 and CYP1B1 expression in the presence of both 5-FU and BP may 
be explained by the additive inducing action of BP via the AhR pathway (Bao et al., 2002). 
However, the potential roles of these pathway interactions need to be investigated further, because 
for CYP1A2, whilst the response to co-treatment was similar to the other CYPs i.e. a steady 
increase from 6 to 24 hours, the expression pattern in response to 5-FU appeared erratic, with a 
down-regulation at 12 hours followed by an up-regulation at 24 hours. Interestingly, the response 
of all three CYPs to the BP + CDDP co-treatment was similar to that of the BP + 5-FU co-
treatment, in that the combined exposure generally led to increased CYP1 expression, compared to 
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the control. It is well-known that the cytotoxic mechanisms of CDDP depend on Cdk2 activity, so 
it is possible that a similar mechanism to that of 5-FU, coupled with BP-mediated induction of 
AhR, is responsible for the increased expression observed throughout (Yu et al., 2007).  
In this study, the level of induction achieved by BP treatment was not always found to be 
consistent, as in the case of CYP1A2 protein induction levels between the 5-FU experiment (~90-
fold, Figure 3.10) and the CDDP experiment (~14-fold, Figure 3.18). This could have been due to 
experimental error, but because the overall trends were reproducible, the difference in cell passage 
numbers between the 5-FU experiment and the CDDP experiment is more likely to have been 
responsible. 
Whilst the possible mechanisms behind the results for the CYPs are noteworthy, this study has 
focused on the clinical relevance of the changes in DME expression observed in response to 
chemotherapy. The differential expression of the DMEs in response to 5-FU and CDDP, if shown 
to be physiologically significant by further research, is likely to affect the metabolism of other co-
administered substances/drugs.  In the example of 5-FU increasing CYP1A1 expression, a cancer 
patient being administered 5-FU may also be taking acetaminophen, which is a widely-used 
analgesic agent that is present in over 600 over-the-counter and prescription drugs for treating pain, 
fever, cough, allergies and more. Acetaminophen is known to be metabolised by CYP1A1, and 
should there be a significant up-regulation of this enzyme by 5-FU, the patient may experience 
acetaminophen toxicity. This is because elevated CYP1A1 levels have been shown to result in 
accumulation of the acetaminophen metabolite N-acetyl-p-benzoquinone-imine, which is a potent 
cytotoxin (Casley et al., 1997; Kim et al., 2009; Laine et al., 2009). In the case of the down-
regulation of CYP1A2 by CDDP, warfarin is one of the most commonly-used anticoagulant drugs 
worldwide and is metabolised by CYP1A2. Should the expression of CYP1A2 be repressed by 
CDDP in a cancer patient on chronic warfarin treatment, the metabolism of warfarin could be 
compromised, possibly leading to ADRs, as has been observed in the previously discussed 
example of 5-FU and CYP2C9 (section 1.3, Figure 1.9). These examples illustrate the importance 
of understanding the effects of the drugs administered to a patient on the DME genes, in order to 
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optimize the therapeutic efficiency of the medication without compromising the metabolism of 
other drugs. 
Unlike in the case of 5-FU, CDDP treatment alone led to irregular changes in CYP1A1 mRNA 
expression at the initial time points, which were later “normalised” to control levels after 24 hours. 
Similarly, CYP1B1 mRNA expression levels were initially decreased by CDDP, but no difference 
from the control was observed after 24 hours. Kitamura et al. (2008) have demonstrated that 
subsequent to induction, CYP1A1 activity is gradually decreased to control levels after 24 hours 
This could explain the effect observed in this study, possibly for CYP1B1 as well, given that both 
CYPs are controlled by the same pathway.  In contrast to the results observed for CYP1A1 and 
CYP1B1, CDDP down-regulated CYP1A2 mRNA expression to levels that were almost 
undetectable. The work of Kitamura et al. (2008) further supports this, because in their study, 
CYP1A2 mRNA levels only returned to control levels 48 hours after treatment. Thus, it is possible 
that the down-regulation of CYP1A2 by CDDP in this study would be corrected at some point after 
24 hours. Further work needs to be done to determine if this is the case, by treating the cells for a 
longer time period. Should the down-regulatory effect of CDDP on CYP1A2 be shown to be 
sustained and to have physiological effects in the cell, there may be important clinical 
consequences for a patient who is being administered this drug. CYP1A2 is primarily detected in 
the liver, and as previously mentioned, this enzyme is responsible for the metabolism of a variety 
of clinically-prescribed drugs, both chemotherapeutic and otherwise, as well as many compounds 
found in the environment and diet. The repressive effect of CDDP on CYP1A2 needs to be 
investigated further in liver cells, in order to ascertain whether this down-regulatory effect can in 
fact be detected at the protein level. This would suggest that patients who rely on the metabolic 
activity of CYP1A2 for the administered co-medications should be carefully evaluated when they 
are on CDDP-containing chemotherapeutic treatment, because the metabolism of co-medication 
may be compromised.  
A further point to note is that when CYP1A2 mRNA expression levels were down-regulated by 
CDDP exposure in this study, low levels of the corresponding protein were still detected by the 
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western blot analysis. Naturally, the synthesis of a protein cannot occur without the initial 
transcription of the relevant mRNA transcript. Given that the amplification specificity of the qRT-
PCR primer sets was comprehensively validated, this phenomenon cannot be explained by 
inefficiencies in the qRT-PCR technique. Instead, there may have been a concurrent up-regulation 
of CYP1A2 expression through increase of the protein’s half-life by stabilization. Alternatively, at 
the time points where total RNA and protein were isolated from the cells, there may have been 
accumulated CYP1A2 protein in sufficient amounts to allow detection by western blot analysis, 
despite the repression of CYP1A2 mRNA expression by the presence of CDDP. 
An additional interesting observation was that the response of the CYPs, particularly CYP1A1 and 
CYP1A2, to both 5-FU and CDDP treatment in combination with BP was a lower expression level 
than what was observed for BP alone, at 24 hours. This was reflected at the protein level as well. 
As previously hypothesised, 5-FU or CDDP treatment may lead to increased CYP1 expression via 
the Cdk2, Nrf2 and/or AhR signalling pathways. A further increase in expression could be 
expected in the presence of BP as well via AhR activation, yet the expression levels are lower in 
response to combined drug and BP treatments than in response to BP alone. This could be 
attributed to the generation of ROS due to increased cellular stress in the presence of two foreign 
compounds. Since CYP activity itself can also produce ROS in the cell, CYP expression is subject 
to a negative-feedback auto-regulatory loop, which ensures that the mRNA and protein levels for 
these enzymes are responsive to the ROS generated (Morel et al., 1999). Thus, in the presence of 
the co-treatment, CYP1A1 and CYP1A2 may have been down-regulated to protect against 
excessive ROS production, and more so as time progressed and more ROS accumulated. This is 
further supported by the similarity in the pattern of findings for CYP1A1 and CYP1A2, because 
these two genes share a bi-directional promoter containing at least 13 AhR response elements, 
some of which regulate both genes in co-ordination (Ueda et al., 2006; Jorge-Nerbert et al., 2010).  
The formation of ROS may have also been responsible for the morphological changes observed in 
the WHCO1 cells.  Interestingly, blebbing cells were observed in the presence of either 5-FU or 
CDDP in combination with BP, but not in the drug-treated cells, the BP-treated cells or the DMSO-
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treated controls. The formation of blebs is a well-characterised sign of early apoptosis (Wickman et 
al., 2013), and excessive ROS production may lead to apoptosis (Circu and Aw, 2010). 
Furthermore, in addition to their critical role in drug metabolism, the CYP1 enzymes also 
participate in various signalling pathways that control cell proliferation as well as apoptosis, and 
the AhR is known to play a role in regulating the cell cycle (Barhoover et al., 2010). A recent study 
by Das et al. (2014) used in silico methods to determine that BP-CYP1B1 complexes show binding 
affinity towards certain caspases, which are the major proteins responsible for apoptosis, whilst 
CYP1B1 knockdown or inhibition suppressed BP-induced apoptosis. It would be of interest to 
replicate this study in CYP1B1-knockdown WHCO1 cells, to determine if the apoptosis was 
indeed caused by BP-CYP1B1 complexes. However in this study, the presence of apoptotic cells 
only in the cell culture dishes treated with 5-FU/CDDP and BP in combination suggests that there 
is some interaction between the drugs and BP that was responsible for apoptosis. Further studies 
comparing the ROS and active caspase levels between cells treated with the drug-BP combination 
vs. BP alone and drug alone, may begin to elucidate the mechanism behind apoptosis. 
Additionally, as previously explained, the potential effects of 5-FU and CDDP on the Cdk2 
pathway may also be involved. It is especially important to determine whether the apoptosis in 
response to combination treatment is tumour-cell-specific because, if non-malignant cells remain 
unaffected, this provides a potential means for enhancing 5-FU/CDDP chemotherapy through the 
use of a CYP1-inducer. The manipulation of DME activity in order to optimize drug therapy is 
well-established. As an example, some current pharmacological approaches include the use of 
GSTP1 inhibitors in cancer treatment, so as to protect the proficiency of chemotherapeutics that 
would otherwise be cleared by GSTP1 activity (Morales and Laborde, 2007).  
The decreased level of induction of CYP1A1/1A2 mRNA in response to 5-FU and BP in 
combination, compared to BP alone, was also observed for CYP1B1 mRNA, although much earlier 
at 6 hours following treatment and then “corrected” by 24 hours. Conversely, exposure to CDDP 
enhanced the CYP1B1-inducing ability of BP initially, but this effect was also reversed by 24 
hours. In general, CYP1B1 is known to be less inducible than the other CYP1 genes (Abel et al., 
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1996; Taylor et al., 2009) and this might be why the DME was less susceptible to the effects of the 
chemotherapeutic drugs on BP-mediated induction than CYP1A1 and CYP1A2. Nevertheless, 
CYP1B1 transcription is also controlled by the AhR pathway, and it would be interesting to 
investigate what mechanism differentiates the response of this gene from that of CYP1A1 and 
CYP1A2 to the chemotherapeutic drugs combined with BP. As mentioned in section 1.4.1, 
CYP1B1 is primarily expressed extra-hepatically and is detectable in a variety of tumours, but is 
usually not present in adjacent normal tissues. This means that there is therapeutic potential for the 
metabolism of chemotherapeutic agents by CYP1B1 specifically in cancer cells, which is why 
understanding the effects of these drugs on the expression of CYP1B1 has great value.  
The purpose of including BP in this study was not only as a positive control of CYP expression, but 
also as a model of CYP induction. As discussed in section 1.3, there are various drugs, 
environmental substances and dietary compounds that are capable of inducing CYP expression. If 
the decrease in CYP1A1/1A2 mRNA and protein expression observed in response to 5-FU/CDDP 
+ BP treatment, compared to BP treatment alone, cannot be explained by future studies (e.g. on 
ROS production), this decrease may have clinical consequences. For a cancer patient prescribed 5-
FU/CDDP and also exposed to a CYP1A1/1A2 inducer, there is the possibility of less available 
CYP1A1/1A2 enzyme and thus decreased metabolism of drugs and exogenous compounds. As an 
example of a CYP-inducing drug, omeprazole is one of the most widely-prescribed drugs 
worldwide and is available over-the-counter in many countries for the treatment of gastro-
oesophageal reflux disease and other conditions caused by excess gastric acid. This drug is also a 
well-known inducer of CYP1A1 and CYP1A2 via the AhR pathway (Andersson, 1996; Frick et al., 
2003; Yoshinari et al., 2008). Hypothetically, if a cancer patient prescribed 5-FU or CDDP is 
concurrently taking omeprazole, there may be reduced levels of these CYP enzymes. 
Consequently, the metabolism of any compounds that require these CYPs will be compromised. 
These compounds are many, including clozapine, caffeine, warfarin, fluvoxamine and paracetamol, 
to name a few for just CYP1A2.  
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It is important to bear in mind that DME expression, particularly CYP expression, is variable 
between individuals, tissues and the tumour type. Thus, whilst baseline mRNA expression levels of 
CYP1A1/1A2 were low in the WHCO1 cell line and required induction to be more easily 
detectable, another patient/tissue/tumour cell type may exhibit mRNA expression levels of these 
CYPs equal to or higher than the induced levels observed in WHCO1, rendering them more 
susceptible to differential expression by 5-FU or CDDP. Assuming that this is the case, it may be 
disadvantageous to administer 5-FU or CDDP to a cancer patient if there is co-medication to be 
metabolised by the CYPs because, should the metabolism of the co-administered drug be 
decreased, accumulation of the drug may lead to toxicity and ultimately, ADRs for the patient. On 
the other hand, should the metabolism of the co-administered drug be increased, the efficiency of 
the drug might be compromised.  
In this study, a slight but significant decrease in GSTP1 mRNA expression was observed in 
response to 5-FU exposure. In terms of 5-FU treatment and GSTP1, little research has been 
performed to investigate the effect of this drug on the expression of detoxification enzymes, and 
many of the existing studies yield conflicting results. For example, a study by Nishiyama et al. 
(1999) has shown that when used alone, 5-FU increases GSTP1 expression at certain 
concentrations. Another study has demonstrated that in human colon cancer cells, the effects of    
5-FU on most of the antioxidant enzymes, including GSTP1, are low to non-existent (Akhdar et 
al., 2009). Furthermore, this study shows that the cytoprotective enzymes that are affected by       
5-FU, namely GSTS1 and GSTM3, increase in their mRNA levels only after 48 hours of 
incubation with 5-FU, due to the nuclear translocation and activation of Nrf2 by 5-FU. Fujishima 
et al. (1997) were unable to show a decrease in GSTP1 expression in response to 5-FU exposure 
despite a marked decrease in the steady-state mRNA levels of two genes coding for rate-limiting 
enzymes for GSH synthesis, after 48 hours of 5-FU treatment. Thus, it is also possible that in this 
study, a greater effect of 5-FU on GSTP1 expression might’ve been observable had the cells been 
treated for a longer period or at different drug concentrations. Nevertheless, the results of this study 
show that should the decreased expression of GSTP1 have a significant physiological impact on the 
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cell, an oesophageal cancer patient taking 5-FU may have reduced levels of available GSTP1, 
which may compromise the detoxification of co-administered drugs as well as other exogenous 
compounds with harmful metabolites. However, the repressive effect of 5-FU may also increase 
the therapeutic efficiency of the drug when immediately followed by CDDP treatment. The 
sequential cytotoxic action of these two drugs has been shown by Scanlon et al. (1986) and is 
currently widely-used for treating tumours of the gastrointestinal tract.  
In contrast to 5-FU, GSTP1 mRNA expression was steadily increased over time in response to 
CDDP treatment. CDDP is known to be conjugated by the GSH enzymes including GSTP1, and 
exposure to CDDP has been shown to up-regulate the expression levels of GSTP1 in other studies 
as well, along with several other detoxification enzymes (Goto et al., 1999; Nishiyama et al., 1999; 
Townsend et al., 2009). For a patient taking CDDP, the increased levels of GSTP1 could lessen 
therapeutic efficacy by detoxifying the drugs too rapidly, leading to cellular resistance to 
chemotherapy, as mentioned in section 1.2. 
It was interesting to note that unlike all of the CYP proteins in response to both chemotherapeutic 
drugs, GSTP1 protein was readily and generally equally detectable under all the treatment 
conditions, including in the control cells. One possible explanation for this is that GSTP1 protein 
might be up-regulated in the WHCO1 cell line, and therefore could not be further induced by 
CDDP, which showed an induction in GSTP1 mRNA expression. This could be confirmed by 
measuring and comparing the basal levels of GSTP1 protein expression in a non-cancerous human 
oesophageal cell line. As mentioned in section 1.2, it has been shown that increased levels of this 
protein could have a protective effect against CDDP-induced toxicity, so patients may have an 
improved response to CDDP chemotherapy. On the other hand, elevated GSTP1 levels may also 
result in cellular resistance to CDDP, thus decreasing the efficacy of chemotherapy (Yellin et al., 
1994; Townsend et al., 2009). Consequently it is important to first and foremost, understand the 
effects of the administered chemotherapeutic agents on the detoxifying enzymes such as GSTP1, 




Throughout the experimental findings of this study, there were varying differences between the 
gene expression level for a given DME and its corresponding level of protein expression. 
Experimental error cannot be completely ruled out; however the trends observed were reproducible 
and thus likely to be a true reflection of the results. Differences between gene and protein 
expression levels for a given gene can be explained by a number of known factors. Gene 
expression is regulated in numerous diverse ways and at different stages. Steady-state RNA levels 
are subject to transcriptional control (e.g. transcription factors, enhancers and silencers) and post-
transcriptional control (e.g. RNA processing including alternative splicing, as well as RNA 
stability). In mammalian cells, an average of two mRNA transcripts is produced per hour, whereas 
dozens of proteins per mRNA per hour are transcribed. At the translational level protein stability is 
an important factor, as the half-life between different proteins can range from minutes to days, 
whilst the degradation rate of mammalian mRNA falls within a much tighter range of up to seven 
hours (Guo et al., 2008). Therefore, although RNA expression levels may have predictive value in 
inferring potential protein expression levels, changes in gene expression are frequently not 
reflected at the protein level. In fact, the correlation between gene and protein expression can be as 
low as 40%, depending on the particular system (Vogel and Marcotte, 2012).  
4.1 Limitations of this study 
 
Although all the objectives of this project were met successfully, there were certain limitations that 
need to be acknowledged: 
 Since DPD is the principal enzyme involved in 5-FU clearance, it would have been 
beneficial to measure the levels of DPD expression in WHCO1 cells. This would serve to 
confirm that the effects of 5-FU on the DMEs measured in this study were not affected by 
a high activity level of DPD and thus, rapid elimination of the drug from the cells. 
 
 5-FU and CDDP are frequently co-administered, especially for the treatment of 
oesophageal cancer. Due to the length of the cell culture experiments and other time 
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constraints, it was not possible to investigate the effect of these two chemotherapeutic 
drugs in combination on the expression of the DMEs, which may have yielded interesting 
potential implications for oesophageal cancer patients. 
 
 
 Genetic variation in the four DMEs was not taken into account in this study, and variations 
such as SNPs can have an impact on the expression levels of the DME genes. It would 
have been useful to genotype the WHCO1 cell line for known SNPs affecting CYP and 
GSTP1 expression, to support the expression data. 
4.2 Future work 
 
This research has yielded several interesting effects of the chemotherapeutic drugs 5-FU and 
CDDP, individually as well as in the presence of BP, on the mRNA and protein expression levels 
of four important DMEs. Firstly, this work serves as a preliminary study for the potential 
physiological significance of the differential expression of the DMEs to be determined. McCarthy 
and Smyth (2009) have described an in silico method to determine the biological relevance of gene 
expression changes, which may be used in future work based on the results of this study. To 
specifically elucidate the possible mechanisms behind the findings of this study, a good starting 
point would be to investigate the effects of 5-FU and CDDP on AhR, Cdk2 and Nrf2 expression 
levels in the WHCO1 cells. Furthermore, it would also be interesting to reproduce this study and 
increase the drug exposure time to determine if the changes observed in response to the various 
treatments are sustained beyond 24 hours and if so, for what length of time. This includes the 
decrease in CYP1A1/1A2 mRNA induction levels by 5-FU/CDDP + BP exposure, compared to BP 
treatment alone, and it should also be determined if this is a result of the CYP negative regulatory 
feedback loop to reduce ROS. If this is not the case and there is some other mechanism behind the 
decrease in CYP1A1/1A2 expression, the timing of a patient’s administration of co-medication 
could be adjusted so as to maximise the required metabolic capacity of these important CYP 
enzymes. Also, as previously discussed, the down-regulatory effect of CDDP on CYP1A2 mRNA 
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expression should be confirmed in future experiments involving liver cells, which have higher 
basal expression levels of CYP1A2.  
Because the expression of the DMEs is highly tissue-specific and this study focused on one cell 
line, it would be of great value to replicate this work using other oesophageal cancer cell lines, as 
well as different tumour cell lines and especially liver cells, given that CYP1A2 is expressed at 
high levels hepatically. This will serve to broaden the perspective on the possible impact of 5-FU, 
CDDP and/or CYP-inducers like BP, on patient response. As mentioned above (section 4.1), future 
work should also entail the use of these drugs in other tumour cell lines harbouring known genetic 
variations in the DME genes as this may affect the response to drug and/or BP treatment. 
Epigenetic factors such as DNA methylation and miRNA regulation also contribute to the response 
















The findings of this research demonstrated that 5-FU and CDDP significantly influence the 
expression of four critically important DME genes, CYP1A1, 1A2, 1B1 and GSTP1. This may have 
important potential clinical consequences for patients with oesophageal cancer, which is a leading 
cause of death worldwide. These consequences include an impact on the metabolism of co-
medication, dietary compounds, nutritional supplements and environmental compounds, leading to 
loss of drug efficacy or the accumulation of cytotoxic metabolites in the body. Furthermore the 
potential decrease of available CYP1A1/1A2 protein in the presence of BP, shown in this study, 
may result in poor metabolism of co-administered drugs, ultimately causing ADRs. This is 
especially important because BP is not only an omnipresent environmental pollutant (Perumal et 
al., 2012), but it is also a model for other CYP-inducers present in both prescription and over-the-
counter drugs and in various dietary substances. This study also showed that combining 5-FU 
and/or CDDP with BP resulted in early apoptosis of the oesophageal cancer cells, which depending 
on future work on non-cancerous cell lines, suggests that the use of CYP-inducers in conjunction 
with these chemotherapeutics may improve therapeutic response. Further studies are required to 
determine the mechanisms behind these effects.  
The management of ADRs in cancer patients is a major challenge, because these reactions can be 
severe or even fatal. Understanding how chemotherapeutic drugs affect the enzymes that 
metabolise over 90% of medication as well as other exogenous and endogenous compounds, is 
crucial for improving patient response. The findings of this research contribute to the current 
knowledge on providing a means for predicting patient response to chemotherapy. Thus, this 
project has laid the foundation for future pharmacogenetics research, an important field which 
seeks to understand the influence of genetics on patient response to drugs, in order to maximise 
therapeutic efficiency whilst minimising adverse effects. The study of pharmacogenetics provides 
the key for the progression of the new era of personalised medicine, a field that holds promise as a 
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All solutions stored at room temperature unless stated otherwise. 
1% Agarose gel with ethidium bromide 
1 g Agarose  
100 mL 1X TBE (in DEPC-treated water) 
Dissolve by pulse-heating in microwave with gentle agitation in between. Allow to cool on shaker 
and add 4 µL ethidium bromide before pouring. 
 
30% Acryl-bisacrylamide mix 
29 g Acrylamide 
1 g N,N’-methylenebisacrylamide 
Dissolve in 60 mL dH2O and heat to 37 ºC. Adjust volume to 100 mL with dH2O and store at 4 ºC 
protected from light. 
 
10% Ammonium persulphate 
1 g ammonium persulphate  
8 mL dH2O 
Adjust volume to 10 mL with H2O. Store at 4 ºC protected from light and use with 2 weeks. 
 
0.5 M EDTA (pH 8.0) 
37.22 g Na2EDTA.2H2O 
140 mL dH2O 
Adjust pH to 8.0 with 10 M NaOH and volume to 200 mL with dH2O, and autoclave. 
 
70% Ethanol 
70 mL Absolute ethanol 
Make up to 100 mL with dH2O 
 
DEPC-treated sterile dH2O 
Add 100 µL DEPC to 100 mL dH2O, stir, leave to stand overnight and autoclave. 
 
5% Fat-free blocking solution 
5 g Fat-free milk powder 





500 mL Methanol 
100 mL Acetic acid 
400 mL dH2O 
Store at room temperature and use within 1 month. 
 
Freezing medium 
1 mL DMSO 
9 mL FCS 
Store at -20 ºC. 
 
1 M HCl 
Add 6.13 µL concentrated HCl to 200 mL H2O. 
 
MTT reagent 
100 g Thiazolyl blue tetrazolium powder 
20 mL 1X PBS 
Incubate at 37 ºC for 15 minutes and store at 4 ºC protected from light for up to 1 month. 
 
10X PBS  
2 g KCl 
80 g NaCl 
2 g KH2PO4 
11.5 g Na2HPO4 




100 mL 10X PBS 
900 mL dH2O 
Store at 4 ºC. 
 
1X PBST 
100 mL 1X PBS 
1 mL Tween-20 
Place on magnetic stirrer for 30 minutes and store at 4 ºC. 
 
8% Resolving gel 
4.6 mL dH2O 
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2.7 mL 30% Acryl-bisacrylamide mix 
2.5 mL 1.5 M Tris (pH 8.8) 
100 µL 10% SDS 
100 µL 10% Ammonium persulphate 
6 µL TEMED 
 
12% Resolving gel 
3.3 mL dH2O 
4.0 mL 30% Acryl-bisacrylamide mix 
2.5 mL 1.5 M Tris (pH 8.8) 
100 µL 10% SDS 
100 µL 10% Ammonium persulphate 
4 µL TEMED 
 
1X RIPA buffer 
1 mL 10X RIPA buffer 
9 mL dH2O 
Store at 4 ºC. 
 
1X RIPA buffer with protease inhibitor cocktail 
10X protease inhibitor cocktail tablet  
2.5 mL 1X PBS  
Dissolve tablet in PBS and add 20 µL of this solution to 180 µL 1X RIPA buffer just before use. 
 
2X RNA loading buffer 
900 µL Formamide 
99 µL Sucrose 
0.5 µL Bromophenol blue 
0.5 µL Xylene cyanol 
 
10% SDS 
10 g SDS 
90 mL dH2O 
Heat to ~70 ºC to dissolve and adjust volume to 100 mL with dH2O. 
 
5X SDS loading buffer 
12.5 mL 2 M Tris-HCl (pH 6.8) 
10 g SDS 
30 mL Glycerol 
5 mL 14.3 M β-Mercaptoethanol 
52 mL Bromophenol blue 
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Adjust volume to 100 mL with dH2O. 
 
10X SDS running buffer 
10 g SDS 
30.3 g Tris 
144.1 g Glycine 
800 mL dH2O 
Adjust volume to 1 L with dH2O. 
 
1X SDS running buffer 
100 mL 10X SDS running buffer 
900 mL dH2O 
 
10X SDS transfer buffer 
144 g Glycine 
38 g Tris 
Adjust volume to 1 L with dH2O. 
 
1X SDS transfer buffer 
100 mL 10X SDS transfer buffer 
200 mL Isopropanol 
700 mL dH2O 
Store at 4 ºC. 
 
Solubilisation reagent 
50 g SLS 
5 mL 1M HCl 
Adjust volume to 500 mL with dH2O. 
 
5% Stacking gel 
2.1 mL dH2O 
500 µL 30% Acryl-bisacrylamide mix 
380 µL 1.5 M Tris (pH 6.8) 
30 µL 10% SDS 
30 µL 10% Ammonium Persulphate 
3 µL TEMED 
 
Stripping buffer 
690 µL 14.3 M β-Mercaptoethanol 
20 mL 10% SDS 
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6.25 mL 1 M Tris-HCl (pH 6.7) 
73.06 mL dH2O 
Store and use in fume-hood. 
 
10X TBE (DEPC-treated) 
108 g Tris 
55 g Boric acid 
40 mL 0.5 M EDTA (pH 8.0) 
Adjust volume to 1 L with DEPC-treated dH2O and autoclave. 
 
1X TBE 
100 mL 10X TBE 
900 mL DEPC-treated dH2O 
 
1.5 M Tris pH 6.8 
60.5 g Tris base 
300 mL dH2O 
Adjust pH to 6.8 with concentrated HCl and volume to 500 mL with dH2O. Store at 4 ºC. 
 
1.5 M Tris pH 8.8 
60.5 g Tris base 
300 mL dH2O 
Adjust pH to 8.8 with concentrated HCl and volume to 500 mL with dH2O. Store at 4 ºC. 
 
1 M Tris-HCl (pH 6.7) 
24.22 g Tris base 
160 mL dH2O 
Adjust pH to 6.7 with concentrated HCl and volume to 200 mL with dH2O. Store at 4 ºC. 
 
1X Trypsin-EDTA 
1 mL 10X Trypsin-EDTA 
9 mL dH2O 










Calculating IC50 values from a sigmoidal-dose response curve using GraphPad PRISM
®
 v 5.0 
software (continued from section 3.2.1) 
After entering the required raw data, which are the concentration gradient values and 
corresponding absorbance readings obtained from the MTT assay (section 2.2.2), the GraphPad 
PRISM
®




Y = Bottom + (Top – Bottom) / 1 + 10
(LogIC50 – X) - Hillslope 
The equation is known as a four-parameter logistic equation, where Bottom refers to the Y value at 
the bottom plateau and Top refers to the Y value at the top plateau of the curve (Figure B1). 
LogIC
50 
is the X value when the response if halfway between the Top and the Bottom. The 
Hillslope, also known as the slope factor or Hill coefficient, describes the steepness of the curve. 
When the Hillslope is positive, the curve increases as X increases as shown in the three examples 
















When the curve goes in an uphill direction, as shown in the example in Figure B1, the variable is 
called the ED
50
 (half maximal effective dose), whereas when the curve goes downhill, as in Figure 
3.2 of this study, the variable is called the IC
50






































Figure C1 Melt curve for CYP1A1 product after qRT-PCR showing primer specificity. Three 
matched peaks can be observed, indicating that the primers amplified a single product (in 













Figure C2 Melt curve for CYP1A2 product after qRT-PCR showing primer specificity. Three 
matched peaks can be observed, indicating that the primers amplified a single product (in 















Figure C3 Melt curve for GSTP1 product after qRT-PCR showing primer specificity. Three 
matched peaks can be observed, indicating that the primers amplified a single product (in 












Figure C4 Melt curve for GAPDH product after qRT-PCR showing primer specificity. Three 
matched peaks can be observed, indicating that the primers amplified a single product (in 






































Size (bp) Size (bp) 
1 2 3 4 1 2 3 
1 2 3 4 5 1 2 3 4 
A B 
C D 
Figure D1 Confirmation of qRT-PCR products by agarose gel electrophoresis. The products 
of the qRT-PCR were electrophoresed on a 1% agarose gel alongside a 100 bp molecular weight maker 
(shown in lane 1 of each gel image). The gel images show the correct fragment sizes for A. CYP1A1 (lanes 
2 and 3), CYP1A2 (lane 4), B. CYP1B1 (lanes 2 and 3), C. GSTP1 (lanes 2-5) and D. GAPDH (lanes 2-4). 
